

## The crossroads between cancer immunity and autoimmunity: antibodies to self antigens

Monica Benvenuto<sup>1</sup>, Rosanna Mattera<sup>1</sup>, Laura Masuelli<sup>2</sup>, Ilaria Tresoldi<sup>1</sup>, Maria Gabriella Giganti<sup>1</sup>, Giovanni Vanni Frajese<sup>3</sup>, Vittorio Manzari<sup>1</sup>, Andrea Modesti<sup>1,4</sup>, Roberto Bei<sup>1,4</sup>

<sup>1</sup>Department of Clinical Sciences and Translational Medicine, University of Rome, Tor Vergata, Rome, 00133 Italy, <sup>2</sup>Department of Experimental Medicine, University of Rome, Sapienza, Rome, 00164 Italy, <sup>3</sup>Department of Sports Science, Human and Health, University of Rome 'Foro Italico', Rome, 00135 Italy, <sup>4</sup>Center for Regenerative Medicine, (CIMER), University of Rome "Tor Vergata", Rome, 00133 Italy

### TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Immune response to self antigens in cancer patients partly covers that characteristic of patients with autoimmune diseases
4. Features of self antigens involved in the autoreactive immune response: immunological properties and abnormal expression
5. Biological activities of autoantibodies to self antigens
6. Association of autoantibodies to self antigens with paraneoplastic autoimmune syndromes
7. Role of autoantibodies to self antigens as biomarkers for cancer detection and cancer patients prognosis
8. Paraneoplastic neurological syndromes, effects of therapy targeting immune-checkpoint receptors and Tregs dysregulation in autoimmune disease patients: the crossroad between autoimmunity and immune response in cancer patients
9. Conclusions
10. Acknowledgment
11. References

### 1. ABSTRACT

The production of autoantibodies to self antigens is dependent on the failure of immune tolerance. Cancer cells express antigens which elicit a spontaneous immune response in cancer patients. The repertoire of autoantibodies found in cancer patients partly covers that of patients with autoimmune diseases. Biological activities of autoantibodies to self antigens may induce paraneoplastic syndromes which reflect the attempt of cancer patients to counteract tumor growth. Autoantibodies with similar specificities may have different effects in cancer and autoimmune disease patients due to different immunological microenvironments. Tregs dysfunction has been observed in patients with paraneoplastic syndromes and/or with autoimmune diseases, while the increase of Tregs has been associated with poor cancer patients prognosis. Novel therapies have employed antibodies against Tregs immune-checkpoint receptors with the aim to boost immune response in cancer patients. The presence of autoantibodies to tumors antigens has also been investigated as a marker for cancer detection and cancer patients prognosis. This report reviews the current knowledge on the analysis and

meaning of autoantibodies to self antigens detected in cancer and autoimmune disease patients.

### 2. INTRODUCTION

The production of autoantibodies to self antigens is dependent on the breakdown or failure of immune tolerance mechanisms toward self-antigens. The immune system does not recognize self-antigens in physiological conditions, but after the failure of immune tolerance these antigens may elicit T and B cells immune response (1). The immune response of autoreactive B cells occurs via central and peripheral tolerance mechanisms. During the central tolerance the autoreactive B cells are eliminated by receptor editing, that leads to rearrangement of light-chain Ig genes to generate a new B cell with non-self-reactive receptors. During peripheral tolerance, the autoreactive B cells are removed via several mechanisms, including inhibition mediated by FcγRIIb, clonal inhibition by the Siglec/SIaE pathway, inhibition by T regulatory cells (Tregs) in an MHC class II- and CD40L-dependent manner, clonal deletion and anergy

(1). In addition, during development autoreactive T cells are initially deleted by negative selection in thymus and then by peripheral tolerance through Tregs, clonal deletion and anergy (2). Thus, defective immune tolerance mechanisms affect autoimmunity by increasing the prevalence of autoreactive lymphocytes. Autoantibodies to self antigens are found both in sera from patients with systemic autoimmune diseases and with cancer (3, 4). However these autoantibodies display a different immunological background leading to different effects in cancer and autoimmune disease. The presence of serum autoantibodies to abnormally expressed tumor antigens might reflect the attempt of cancer patients to counteract cancer cells growth, while autoantibodies found in autoimmune disease are the result of breakdown of self-tolerance and induce pro-inflammatory responses and tissue injuries (5).

### 3. IMMUNE RESPONSE TO SELF ANTIGENS IN CANCER PATIENTS PARTLY COVERS THAT CHARACTERISTIC OF PATIENTS WITH AUTOIMMUNE DISEASES

Cancer cells express tumor antigens able to elicit a spontaneous immune response in cancer patients. Of note, the repertoire of autoantibodies found in cancer patients partly covers that characteristic of patients with autoimmune diseases (5). These autoantibodies might be useful as diagnostic or prognostic markers in cancer patients and as serological markers for the diagnosis of autoimmune diseases (6, 7). Table 1 reports examples of autoantibodies found both in cancer and autoimmune disease patients (5, 8-168).

Specific autoantibodies against nuclear antigens were detected both in cancer and in autoimmune disease patients. These autoantibodies recognized single- and double-stranded DNA, Ro/SS-A, La/SS-B, centromere, Jo-1, Smith antigens (Sm), small nuclear ribonucleoproteins (snRNP), topoisomerase I and II, nucleolar phosphoprotein B23/nucleophosmin, nucleolar organizer antigen NOR-90 and RNA polymerase III (5, 8-30). For example, anti-Ro/SS-A and anti-La/SS-B were prevalent in patients with Sjogren's syndrome (13) and systemic lupus erythematosus (SLE) (11) and in patients with hematological malignancies as well (5). Among the others, autoantibodies to p53, MDM-2, c-Myc and c-Myb were frequently detected in cancer and autoimmune disease patients. Autoantibodies against p53 were found in gastric, ovarian, colorectal, breast, head and neck cancer patients as well as in patients with SLE, rheumatoid arthritis (RA), dermatomyositis, autoimmune thyroiditis and hepatitis, primary biliary cirrhosis and systemic sclerosis (5, 31, 32). Autoimmune disease and cancer patients have also been found to exhibit autoantibodies against MDM-2, which is the p53 inhibitor (33, 34). Anti-c-Myc autoantibodies have been reported to occur in patients

with gastric, breast, colon and ovarian cancer as well as in patients with SLE, Graves' disease, mixed connective tissue disease, dermatomyositis and autoimmune hemolytic anemia (5, 27, 34-39). Patients with colon, ovarian, breast and lung cancer as well as patients with SLE have been found to produce autoantibodies against the c-Myb protein (40). Both categories of patients generate autoantibodies against cyclin-B1, survivin, p16, 14-3-3 proteins, eukaryotic translation initiation factor 4G (eIF-4G) and RAF1 (14, 27, 28, 34-36, 40-48). Autoantibodies against the cyclic citrullinated peptide (CCP) were detected in patients with Sjogren's syndrome and psoriatic arthritis (51, 52) as well as in lymphoma patients (49). Anti-CCP antibodies are highly specific for RA and have recently been used in the clinical classification of this disease. These antibodies are more specific than rheumatoid factor (RF) for the diagnosis of RA (50). Furthermore, anti-RF antibodies are present in about 74% of patients with Sjogren's syndrome, in particular in the early stage of disease, and also in patients with autoimmune pancreatitis (13). Serum of patients with melanoma, bladder and gastrointestinal cancers contain anti-CCP autoantibodies as well (53, 54). Circulating autoantibodies against smooth muscle antigens (ASMA), including actin, troponin and tropomyosin, have been detected in patients with hepatocarcinoma, lung, breast, gastric, ovarian, melanoma, cervix, thymoma cancers, as well as in patients with Sjogren's syndrome, autoimmune hepatitis and pancreatitis, primary biliary cirrhosis and other autoimmune diseases (12, 19, 20, 55, 56, 58-62). The principal autoantibodies against the thyroid gland are anti-thyroid peroxidase (TPO), anti-thyroglobulin (TG) and anti-thyroid stimulating hormone receptor (TSH-R). Indeed, anti-TPO and anti-TG antibodies are mainly detected in patients with Hashimoto's thyroiditis, but they also occur in 70% of patients with Graves' disease (169). In addition, patients with diabetes, RA, systemic sclerosis, celiac disease, autoimmune gastritis, Sjogren syndrome as well as cancer patients with gastric MALT-type lymphoma, breast and thyroid cancer also display autoantibodies anti-TPO and anti-TG (5, 51, 63-73). Autoantibodies to extracellular matrix (ECM) components, including collagen, fibronectin and laminin, have been reported in RA, autoimmune thyroiditis, SLE, systemic sclerosis, Crohn's disease, primary Raynaud's disease, epidermolysis bullosa and pemphigo. Sera from patients with breast, prostate, lung and nasopharyngeal cancers displayed anti-ECM components autoantibodies (5, 11, 74-80). Autoimmune disease and cancer patients also exhibit autoantibodies against heat shock proteins (HSP), including HSP-60, -70, -90 and glucose-regulated protein 78 (GRP78). Autoantibodies against one or more HSPs have been found to occur in patients with SLE, RA, Sjogren's syndrome, mixed connective tissue diseases, diabetes, Behçet's disease, autoimmune retinopathy, encephalomyelitis and hepatitis, dermatitis herpetiformis and juvenile dermatomyositis, as well as

**Autoantibodies to self antigens in cancer patients**

**Table 1.** Examples of autoantibodies to self antigens found both in patients with cancer and autoimmune disease.

| Autoantibodies        |  | Cancer site or histological subtype   | Autoimmune disease   | References                |
|-----------------------|--|---|--|---------------------------|
| Anti-nuclear antigens | Anti-Dna   | Hematological malignancies, lymphoma, ovary, HCC, stomach, colon-rectum   | SLE, AIH-PBC overlap   | 5, 8-12                   |
|                       | Anti-Ro/SS-A   | Lymphoma, hematological malignancies  | SS, SLE, RA, PBC, dermatomyositis, SS-SLE overlap, systemic sclerosis                                  | 5, 8, 11, 13-15           |
|                       | Anti-La/SS-B   | Breast, lymphoma, SCLC, hematological malignancies  | SS, SLE  | 5, 8, 11, 13              |
|                       | Anti-CENP  | Breast, SCLC, NHL, HCC  | SS, SLE, RA, systemic sclerosis, PBC   | 5, 14, 16-19              |
|                       | Anti-Jo-1  | Stomach, lymphoma   | SS, polymyositis   | 8, 20, 21                 |
|                       | Anti-Sm  | Hematological malignancies, kidney, lymphoma, gastrointestinal, ovary   | SLE, mixed connective tissue disease   | 5, 8, 11, 21              |
|                       | Anti-U1 snRNP  | Lung  | SLE, mixed connective tissue disease   | 5, 11, 22                 |
|                       | Anti-U3 snRNP  | HCC   | Systemic sclerosis   | 5, 14                     |
|                       | Anti-Topoisomerase I (Scl-70)  | Stomach, lymphoma   | Systemic sclerosis, SLE, mixed connective tissue disease   | 8, 14, 20, 21             |
|                       | Anti-Topoisomerase II  | Breast, HCC   | Juvenile RA, diabetes mellitus, SLE, localized scleroderma, systemic sclerosis, dermatomyositis        | 23-25                     |
|                       | Anti-B23/ Nucleophosmin  | HCC, breast, prostate, ovary, pancreas, lung, colon   | Systemic sclerosis, RA, SLE, scleroderma   | 5, 26-29                  |
|                       | Anti-NOR-90  | HCC   | Systemic sclerosis, Raynaud's syndrome, RA, SLE  | 5, 14                     |
|                       | Anti-RNA Polymerase III  | Breast  | Systemic sclerosis   | 14, 30                    |
|                       | Anti-p53   | Stomach, ovary, colon-rectum, breast, esophagus, head and neck, HCC, bladder, lung, cervix, uterus, pancreas, lymphoma, biliary tract, hematological malignancies, prostate, glioma, skin | SLE, RA, dermatomyositis, AITD, AIH, PBC, AIH-PBC overlap, systemic sclerosis                          | 5, 31, 32                 |
|                       | Anti-MDM2  | Lung, prostate  | SLE, systemic sclerosis  | 33, 34                    |
| Anti-c-Myc            | Stomach, lung, breast, colon, ovary, HCC, hematological malignancies, prostate | SLE, Graves' disease, mixed connective tissue disease, dermatomyositis, autoimmune hemolytic anemia   | 5, 27, 34-39   |                           |
| Anti-c-Myb            | Colon, ovary, breast, lung   | SLE   | 40   |                           |
| Anti-Cyclin-B1        |  | Lung, breast, HCC, prostate   | SLE, systemic sclerosis  | 27, 34, 36, 40            |
| Anti-Survivin         |  | Stomach, ovary, pancreas, lung, colon, breast, HCC, prostate  | SLE, systemic sclerosis  | 14, 28, 34, 35, 41        |
| Anti-p16              |  | Lung, breast, HCC, prostate   | SLE, systemic sclerosis  | 27, 34, 36, 42            |
| Anti-14-3-3 proteins  |  | Lung, HCC, prostate   | RA, SLE, systemic sclerosis  | 27, 34, 43, 44            |
| Anti-eIF-4G           |  | Prostate  | RA   | 45, 46                    |
| Anti-RAF1             |  | Colon-rectum  | Autoimmune inner ear disease   | 47, 48                    |
| Anti-CCP              |  | Diffuse large B-cell lymphoma   | RA, SS, psoriatic arthritis  | 49-52                     |
| Anti-RF               |  | Bladder, melanoma, gastrointestinal   | SS, autoimmune pancreatitis, RA, SLE   | 11, 53-57                 |
| ASMA                  | Anti-Actin<br>Anti-Troponin<br>Anti-Tropomyosin                                | Stomach, HCC, melanoma, lung, breast, ovary, cervix, thymoma  | SS, AIH, autoimmune pancreatitis, PBC, AIH-PBC overlap, celiac disease, primary sclerosing cholangitis | 12, 19, 20, 55, 56, 58-62 |

**Autoantibodies to self antigens in cancer patients**

|                             |   |  |  |                              |
|-----------------------------|---|--|--|------------------------------|
| Anti- Thyroid antigens      | Anti-TPO                                      | Gastric MALT-type lymphoma, breast, papillary thyroid                                  | AITD, type 1 diabetes, RA, celiac disease, systemic sclerosis, autoimmune gastritis  | 5, 51, 63-68                 |
|                             | Anti-TG                                       | DTC, papillary thyroid, gastric MALT-type lymphoma                                     | AITD, type 1 diabetes, RA, SS, autoimmune gastritis  | 5, 69-73                     |
| Anti-ECM components         | Anti-Collagen                                 | Lung, prostate   | RA, PV, SLE, epidermolysis bullosa, systemic sclerosis, Hashimoto's thyroiditis, Graves' disease, Chron's disease, Raynaud's disease                                 | 5, 74-78                     |
|                             | Anti-Fibronectin                              | Nasopharyngeal, prostate   | RA, SLE, Hashimoto's thyroiditis   | 5, 74, 78                    |
|                             | Anti-Laminin                                  | Breast, prostate   | SLE, PV, systemic sclerosis, Raynaud's disease, Hashimoto's thyroiditis  | 11, 76, 78-80                |
| Anti-HSPs                   | Anti-HSP60                                    | HCC, breast, ovary, osteosarcoma, colon-rectum, gastric MALT-type lymphoma             | Behçet disease, type 1 diabetes, SLE, RA, mixed connective tissue disease, autoimmune retinopathy, dermatitis herpetiformis, juvenile dermatomyositis, AIH           | 5, 17, 81-86                 |
|                             | Anti-HSP70                                    | Breast, HCC, nasopharyngeal  | Dermatitis herpetiformis, AIH  | 36, 84, 86-88                |
|                             | Anti-HSP90                                    | Ovary, multiple myeloma, cholangiocarcinoma, breast, osteosarcoma, prostate            | Dermatitis herpetiformis, autoimmune encephalomyelitis, RA, SLE, autoimmune bullous diseases, type 1 diabetes, AIH   | 5, 28, 74, 79, 84, 86, 89-91 |
|                             | Anti-GRP78                                    | HCC, colon-rectum, prostate, ovary   | RA, SLE, SS  | 28, 92-95                    |
| Anti-onconeural antigens    | Anti-Hu (ANNA-1)                              | SCLC   | Autoimmune limbic encephalopathy non paraneoplastic  | 96, 97                       |
|                             | Anti-Ri (ANNA-2)                              | SCLC, breast, ovary  | Opsoclonus myoclonus syndrome  | 40, 98                       |
| Anti-enzymes                | Anti- $\alpha$ -enolase                       | Lung, pancreatic ductal, breast, leukemia, head and neck, melanoma, esophagus          | SLE, mixed connective tissue disease, systemic sclerosis, Behçet's disease, RA, Hashimoto's encephalopathy, celiac disease, AIH, PBC, primary sclerosing cholangitis | 5, 99-105                    |
|                             | Anti-GAD                                      | Lung, breast, thymoma  | Type 1 diabetes, non-paraneoplastic limbic encephalitis, Stiff-person syndrome, cerebellar ataxia, Batten disease  | 60, 106-108                  |
|                             | Anti-Tyrosinase                               | Melanoma   | Vitiligo   | 109                          |
|                             | Anti-Transglutaminase                         | Lymphoid malignancies  | Celiac disease, autoimmune polyendocrine syndrome type 1, SS, type 1 diabetes  | 5, 110, 111                  |
|                             | Anti-CA II                                    | Pancreas, melanoma   | SS, SLE, RA, autoimmune pancreatitis, autoimmune retinopathies, type 1 diabetes, PBC, Graves' disease, systemic sclerosis, autoimmune endometriosis                  | 55, 56, 112-120              |
|                             | Anti-GAPDH                                    | HCC  | SLE  | 87, 121                      |
|                             | Anti-Peroxiredoxin                            | Prostate, breast, esophagus, lung, HCC   | SLE, RA, Behçet's disease, vasculitis syndrome, systemic sclerosis   | 14, 36, 87, 122-126          |
|                             | Anti-SOD                                      | HCC, lung  | RA, SLE  | 87, 127, 128                 |
| Anti-Factor XIII            | Lymphoid malignancies                         | Celiac disease, autoimmune haemorrhagic-philic, primary anti-phospholipid syndrome, RA | 5, 129-131   |                              |
| Anti-Ribosomal P proteins   | Head and neck, breast, prostate, colon-rectum | SLE, AIH, mixed connective tissue disease  | 11, 74, 132- 136   |                              |
| Anti-Mitochondrial antigens | Breast  | PBC, SS, AIH, RA, SLE  | 11, 13, 73, 137, 138   |                              |
| Anti-Centrosome             | Breast  | RA, SLE, scleroderma   | 139  |                              |

## Autoantibodies to self antigens in cancer patients

|                             |                   |  |   |                     |
|-----------------------------|-------------------|--|---|---------------------|
| Anti-Receptors              | Anti-Fas receptor | Colon  | SLE, systemic sclerosis, silicosis  | 140, 141            |
|                             | Anti-ER           | Breast   | SLE, systemic sclerosis   | 142, 143            |
|                             | Anti-AChR         | Thymoma  | Myasthenia gravis   | 144, 145            |
| Anti-VGCC                   |                   | SCLC   | Lambert-Eaton syndrome  | 40, 146             |
| Anti-CD20                   |                   | NHL, CLL   | RA, SLE, SS   | 5, 147, 148         |
| Anti-Annexin                |                   | Lung, colon-rectum, prostate, breast, ovary                              | Anti-phospholipid syndrome, SLE, RA, systemic sclerosis, connective tissue disease, autoimmune rheumatic disease, polymyositis                      | 47, 122, 149-152    |
| Anti- $\alpha$ -fetoprotein |                   | HCC, colon-rectum  | SLE, juvenile Batten disease  | 5, 17, 47, 153      |
| Anti-Phospholipids          |                   | Breast, hematological malignancies, lung, colon-rectum, melanoma, kidney | RA, SLE, anti-phospholipid syndrome, systemic sclerosis, mixed connective tissue disease, Behçet's disease, systemic sclerosis, systemic vasculitis | 5, 11, 154-159      |
| Anti-Dsg-1/Dsg-3            |                   | NHL, chronic lymphocytic leukemia  | PV  | 160, 161            |
| Anti-Cytokeratin 8          |                   | Head and neck, breast, lung, cervix, bronchi, HCC                        | RA, AIH   | 162-165             |
| Anti-IMP                    |                   | HCC, breast, colon, prostate, ovary, stomach                             | SLE   | 17, 34-36, 166, 167 |
| Anti-IFN- $\alpha$          |                   | Thymoma  | Autoimmune polyendocrinopathy syndrome type 1   | 5                   |
| Anti- $\alpha_2$ -HSG       |                   | Breast   | Autoimmune endometriosis  | 120, 168            |

HCC: Hepatocellular carcinoma; SLE: Systemic lupus erythematosus; AIH: Autoimmune hepatitis; PBC: Primary biliary cirrhosis; RA: Rheumatoid arthritis; SS: Sjögren's syndrome; SCLC: Small cell lung cancer; CENP: Centromere nuclear protein; NHL: non-Hodgkin lymphoma; Jo-1: Istitidil-tRNA sintetasi; Sm: Smith antigen; snRNP: small nuclear ribonucleoprotein; AITD: Autoimmune thyroid disease; eIF-4G: Eukaryotic translation initiation factor-4G; CCP: Cyclic citrullinated peptide; RF: Rheumatoid factor; ASMA: Anti-smooth muscle antibodies; TPO: Thyroid peroxidase; DTC: Disseminated tumor cells; TG: Thyroglobulin; PV: Pemphigus vulgaris; HSP: Heat shock protein; GRP78: Glucose-regulated protein 78; ANNA: Anti-neuronal nuclear antibody; GAD: Glutamic acid decarboxylase; CA II: Carbonic anhydrase II; GADPH: Glycerinaldehyde 3-phosphate dehydrogenase; SOD: Superoxide dismutase; ER: Estrogen receptor; AchR: Acetylcholine receptor; VGCC: Voltage-gated calcium channels; CD20: B-lymphocyte antigen CD20; CLL: Chronic lymphocytic leukemia; Dsg: Desmoglein; IMP: Insulin-like growth factor II mRNA-binding protein; IFN: Interferon;  $\alpha_2$ -HSG:  $\alpha_2$ -Heremans Schmid-glycoprotein.

in patients with osteosarcoma, HCC, breast, ovarian and other types of cancer (5, 17, 28, 36, 74, 79, 81-95). Autoantibodies against onconeural antigens, like Hu (ANNA-1) and Ri (ANNA-2) and against enzymes, like  $\alpha$ -enolase, glutamate decarboxylase (GAD), tyrosinase, transglutaminase, carbonic anhydrase II (CAII), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), peroxiredoxin, superoxide dismutase (SOD) and coagulation factor XIII, have been reported in both patients with autoimmune diseases and cancer (5, 14, 36, 40, 55, 56, 60, 87, 96-131). Circulating autoantibodies against the ribosomal P proteins (P0, P1 and P2) are directed mainly to the carboxy-terminal epitope common to all three proteins and have been identified for the first time in SLE patients. Patients with autoimmune hepatitis and mixed connective tissue diseases display these antibodies too. We have recently demonstrated the presence of autoantibodies against P proteins in head and neck, breast, prostate and colorectal cancer patients (11, 74, 132-136). Patients with autoimmune diseases and cancer also exhibit autoantibodies against mitochondrion and centrosome antigens (11, 13, 73, 137-139). In addition, the presence of autoantibodies against several membrane receptors, including Fas receptor, estrogen recep-

tor (ER) and acetylcholine receptor (AChR) has been reported in sera of patients with various autoimmune diseases and with cancer (140-145). Anti-voltage-gated calcium channel (VGCC), anti-CD20, anti-annexin, anti- $\alpha$ -fetoprotein, anti-phospholipid, anti-desmoglein (DSG), anti-cytokeratin-8, anti-insulin-like growth factor II mRNA-binding proteins (IMP), anti-interferon (IFN)- $\alpha$  and anti- $\alpha_2$ -HSG (Heremans Schmid-glycoprotein) autoantibodies have also been found in sera from patients with cancer and autoimmune disease (5, 11, 17, 34-36, 40, 47, 120, 122, 146-168).

### 4. FEATURES OF SELF ANTIGENS INVOLVED IN THE AUTOREACTIVE IMMUNE RESPONSE: IMMUNOLOGICAL PROPERTIES AND ABNORMAL EXPRESSION

The events inducing the generation of autoantibodies recognizing common antigens in cancer and autoimmune disease patients are still not completely clear. However, some theories have been proposed. Plotz described that the features of self antigens that might induce the production of autoantibodies can be related to: a) their structural properties; b) their catabolism and fate after cell death;



c) their concentration and type of microenvironment; d) their immunological/pro-inflammatory properties (170).

Among the structural properties, the binding of a self antigen to nucleic acid or the presence of a highly charged surface, or repetitive surface elements, or a coiled-coil in a self antigen might promote autoreactive immune response (170). Other observations suggested that the removal of death cells could induce the production of antibodies to self antigens. Necrosis is commonly considered as a pro-inflammatory and immunogenic type of death, which furnishes “danger signals” able to activate the innate immune response and then the adaptive immunity (171, 172). Indeed, self antigens are expressed on the surface of apoptotic or necrotic cells or, are modified by cell-death-mediated protein proteolysis or by molecules cleavage as occurs for nucleic acid antigens (170). The presence of cleavage sites for caspases, Granzyme B or cathepsins in autoantigens may lead to presentation of cryptic epitopes capable of stimulating autoreactive T and B lymphocytes (170, 173).

Another important issue is related to changes in autoantigen cancer cells expression. The overexpression or the expression in aberrant place of a given self antigen could induce immune responses in cancer patients. In addition, autoantibodies generation may also be due to an altered protein structure. Neopeptides exposure, mutations and post-translational antigens modifications, such as glycosylation, methylation, phosphorylation, sumoylation, citrullination, adenosine diphosphate-ribosylation, ubiquitination, and acetylation, can overcome self tolerance mechanisms. In particular, post-translational modifications can influence the recognition of self antigen by the immune system, by affecting antigen processing, by binding and interaction of the MHC with the T cell receptor (TCR) (3). Targeting neopeptides/neoantigens is a new therapeutic strategy for cancer, because these antigens might elicit specific T cell responses and lead to tumor regression (174, 175).

The selection of the autoantibody repertoire shared by patients with cancer and autoimmune disease can be further influenced by the immunological and pro-inflammatory properties of a given self antigen. It has been demonstrated that several self antigens, including asparaginyl and histidyl-tRNA synthetases, U3/fibrillarin, ssDNA plus La/SS-B, and topoisomerase I can act as chemoattractants for leukocytes when released from damaged cells, thus inducing inflammation and autoimmunity (5, 176).

Finally, an autoimmune response may be due to molecular mimicry. In fact an immune response against an infectious agent can elicit a cross-reaction against human proteins with structural similarity (173).

## 5. BIOLOGICAL ACTIVITIES OF AUTOANTIBODIES TO SELF ANTIGENS

Autoantibodies occurring both in cancer patients and in autoimmune diseases exert several biological and pathogenic effects, that can modulate tumor growth and survival. Table 2 reports examples of biological effects exerted by autoantibodies to self antigens (9, 64, 94, 132, 133, 154, 177-202).

Kowal *et al.* reported that autoantibodies against dsDNA found in cerebrospinal fluid have the ability to cross-react with the NR2 glutamate receptor, leading to apoptotic neuronal death in the mouse hippocampus (177). In addition, these autoantibodies generate an inflammatory response due to their deposition as immune complexes in kidney and are able to penetrate into living cells and triggering apoptosis in mesangial and endothelial cells (9). dsDNA autoantibodies possess both *in vitro* and *in vivo* anti-tumor activities through the induction of apoptosis in myeloma and fibrosarcoma cell lines (9). Antinuclear antibodies (ANAs) increase the inflammation through the formation of immune complexes that can induce the production of cytokines or can deposit in the kidney tissue leading to systemic lupus erythematosus. The extracellular release of nuclear antigens is essential for the formation of these immune complexes. It has suggested that the pyroptosis can trigger antigens release in genetically predisposed individuals (178). Robitaille *et al.* demonstrated that autoantibodies to CENP-B inhibited the CENP-B-mediated production of IL-8 and also the transactivation of EGFR in vascular smooth muscle cells (179). A recent study demonstrated the enhanced phagocytosis by neutrophils in RA patients owing RF and anti-CCP autoantibodies. They showed that these autoantibodies indirectly increased the phagocytic capacity of neutrophils. In addition, RF and anti-CCP antibodies possess the ability to activate the complement system cascades, leading to the increase of the inflammatory process and then tissue damage in RA (180). Anti-citrullinated protein antibodies (ACPAs) in patients with RA are associated with inflammation and subsequent joint destruction and deformity. ACPAs bind to monocyte surface-expressed citrullinated GRP78 and stimulate TNF- $\alpha$  production and decrease let-7a miRNA expression. Lu *et al.* demonstrated that ACPAs contribute to inflammation by stimulating TNF- $\beta$  production via binding to citrullinated GRP78 protein and following NF- $\kappa$ B activation on monocyte/macrophages (181). Furthermore, Lu *et al.* recently observed the ACPAs bind to citrullinated HSP-60 on the plasmamembrane of the osteosarcoma cell line Saos-2 and induce apoptosis through Toll-like receptor 4 (TLR4) signaling. Furthermore, ACPAs increase the expression of IL-6 and IL-8 in Saos-2 cells. RA patients with higher titer of anti-citrullinated HSP-60 antibodies showed severe joint damage, suggesting

**Table 2.** Examples of biological activities of autoantibodies to self antigens found in cancer and in autoimmune disease patients.

| Autoantibodies                    | Biological activities   | References |
|-----------------------------------|---|------------|
| Anti-dsDNA                        | Apoptotic neuronal death (mouse hippocampus)  | 177        |
|                                   | Deposition of immune complexes in kidney and generation of inflammation, penetration in living cells, induction of apoptosis (mesangial and endothelial cells)                      | 9          |
|                                   | Induction of apoptosis (myeloma and fibrosarcoma cells)   | 9          |
| Anti-Nuclear antigens             | Formation of immune complexes, increase of inflammation or deposition of immune complexes in the kidney   | 178        |
| Anti-CENP-B                       | Inhibition of CENP-B-mediated production of IL-8 and transactivation of EGFR in vascular smooth muscle cells  | 179        |
| Anti-CCP                          | Increase of phagocytic capacity of neutrophils and activation of complement system cascades   | 180        |
| ACPA                              | Stimulation of TNF- $\alpha$ and - $\beta$ production and decrease of let-7a miRNA expression; NF- $\kappa$ B activation on monocyte/macrophages via binding to citrullinated GRP78 | 181        |
|                                   | Induction of apoptosis through TLR4 signaling via binding to citrullinated HSP-60   | 182        |
| ANCA                              | Activation of cytokine-primed neutrophils and production of ROS   | 183        |
| Anti-TPO                          | Activation of ADCC and CDC; anti-proliferative activity in papillary thyroid cancer cells   | 64, 184    |
| Anti-GRP78                        | Induction of proliferation and protection of prostate cancer cells from TNF-induced apoptosis   | 94         |
| Anti-GRP78 (COOH-terminal domain) | Inhibition of cellular proliferation and induction of apoptosis in melanoma and prostate cancer cells   | 186, 187   |
|                                   | Decrease invasion and increase H <sub>2</sub> O <sub>2</sub> -induced apoptosis of ovarian cancer cells   | 188        |
| Anti-HSP60, -HSP70                | Enhancement of pro-inflammatory cytokines and chemokines production via TLR signaling in monocyte cells   | 189        |
| Anti-Hu                           | Induction of neuronal cell death in the absence of T cell-mediated immune response or ADCC  | 190        |
| Anti-Yo                           | Induction of cytotoxicity through a non apoptotic cell death in Purkinje cells  | 191        |
| Anti- $\alpha$ -enolase           | Induction of apoptosis in endothelial and retinal cells   | 193, 194   |
|                                   | Reduction of the migration and invasion capacity of pancreatic ductal adenocarcinoma cells  | 195        |
| Anti-Ribosomal P proteins         | Inhibition of apolipoprotein B synthesis in hepatoma cells  | 196        |
|                                   | Impairment of memory and induction of apoptosis in brain cells and in Jurkat cells; inhibition of cell proliferation by inhibition of activation of Erk and Akt                     | 196        |
|                                   | Delay of mammary carcinoma growth in a murine model of breast cancer  | 133        |
|                                   | Inhibition of <i>in vitro</i> cancer cell growth in colon cancer cells  | 134        |
| Anti-ER                           | Erk activation and cell proliferation in breast cancer cells  | 142        |
| Anti-AchR                         | Activation of apoptolysis in pemphigus vulgaris   | 197        |
| Anti-VGCC                         | Block Ca <sup>2+</sup> influx and inhibition of cell growth in SCLC cell lines  | 198        |
| Anti-Phospholipids                | Increase of leukocyte infiltration and tumor invasion in breast cancer  | 154        |
|                                   | Alteration of the inner mitochondrial membrane and of the normal apoptotic turnover of the syncytiotrophoblast  | 199        |
| Anti-Dsg1, -Dsg3                  | Induction of apoptosis through the increase of Bax, p53, Fas ligand and receptor, and activation of caspases; activation of EGFR- and apoptosis (FasR)-mediated signaling pathways  | 200        |
| Anti-Aquaporin-4                  | Induction of oligodendrocyte death, myelin loss and neuron death through complement-dependent astrocyte cytotoxicity  | 201        |
|                                   | Induction of astrocytopathy, in the absence of complement activation and immune cell infiltration in Devic's neuromyelitis optica   | 202        |

dsDNA: Double-strand DNA; CENP-B: Centromere nuclear protein-B; IL: Interleukin; EGFR: Epidermal growth factor receptor; CCP: Cyclic citrullinated peptide; ACPA: Anti-citrullinated proteins antibody; TNF: Tumor necrosis factor; NF- $\kappa$ B: Nuclear factor- $\kappa$ B; GRP78: Glucose-regulated protein 78; TLR: Toll-like receptor; HSP: Heat shock protein; ANCA: Anti-neutrophil cytoplasmic antibody; ROS: Reactive oxygen species; TPO: Thyroid peroxidase; ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity; Erk: Extracellular signal-regulated kinases; Akt: Protein kinase B; ER: Estrogen receptor; AchR: Acetylcholine receptor; VGCC: Voltage-gated calcium channels; SCLC: Small cell lung cancer; Dsg: Desmoglein.

a role of membrane-expressed citrullinated HSP-60 and ACPAs in the pathogenesis of RA (182). Falk *et al.* demonstrated that anti-neutrophil cytoplasmic antibodies (ANCA), through the binding to antigen on neutrophil surface, activate cytokine-primed neutrophils and produce reactive oxygen species

(ROS). ANCA also induces the release of primary granule contents. They suggested that ANCA can release toxic oxygen radicals and noxious granule constituents leading to vascular injury in patients with pauci-immune necrotizing vasculitis and pauci-immune crescentic glomerulonephritis (183).

## Autoantibodies to self antigens in cancer patients

Anti-TPO autoantibodies play a role in the induction of thyroid dysfunction and also in the progression of the disease through cytotoxic mechanisms. TPO autoantibodies can damage thyroid cells by antibody- and complement-dependent cytotoxicity (ADCC and CDC). It has been demonstrated that monocytes are the effector cells and contribute with T cells to the destruction of thyroid gland mediated by anti-TPO antibodies in autoimmune thyroid disease (184). Anti-Tg autoantibodies are implicated in the destruction of thyroid gland and in the initiation of autoimmune thyroiditis (185). Furthermore, anti-TPO autoantibodies showed anti-proliferative activity in papillary thyroid cancer cells (64).

GRP78 is a chaperone protein of the endoplasmic reticulum and belong to the HSP70 family. It has been demonstrated that prostate cancer patients possess autoantibodies to GRP78, that bind to a site on the protein also recognized by its physiological agonist,  $\alpha$ 2-macroglobulin. These autoantibodies are able to induce proliferation of prostate cancer cells and protect them from TNF-induced apoptosis (94). In contrast, it has been reported that antibodies against the COOH-terminal domain of GRP78 inhibit cellular proliferation and induce apoptosis in melanoma and prostate cancer cells (186, 187). Patients with ovarian cancer possess autoantibodies against the COOH-terminal domain of GRP78 and these antibodies show the ability to decrease invasion and increase  $H_2O_2$ -induced apoptosis of ovarian cancer cells, suggesting a protective role of these antibodies in this type of cancer (188).

Several studies also demonstrated that autoantibodies against other HSPs exert biological activities. In particular anti-HSP60 autoantibodies are cytotoxic to endothelial cells, and anti-HSP60 and -HSP70 autoantibodies also enhance pro-inflammatory cytokines and chemokines production via TLR signaling in monocyctic cells (189).

Anti-Hu and anti-Ri antibodies were shown to be internalized and accumulated into hippocampal and cerebellar neurons, but only anti-Hu antibodies were able to induce neurone cell death, in the absence of T cell-mediated immune response or antibody-dependent cellular cytotoxicity (190). It has also reported that anti-Yo antibodies have the capacity to induce cytotoxicity through a non apoptotic cell death, but only in Purkinje cells (191). Indeed, anti-Yo antibodies recognize cytoplasmic 62 kDa Yo antigen in Purkinje cell. This antigen plays an essential role in Purkinje cell survival and thus the binding of the antibody can induce cell death (192).

Anti- $\alpha$ -enolase autoantibodies were able to induce apoptosis in endothelial and in retinal cells (193, 194). In particular, these antibodies were able to inhibit the catalytic function of enolase, to deplete ATP, to elevate intracellular  $Ca^{2+}$ , leading to Bax translocation

to the mitochondria and release of cytochrome *c* into the cytoplasm (194). In addition, it has been reported that the *in vitro* and *in vivo* inhibition of  $\alpha$ -enolase-1 with specific monoclonal antibodies reduces the migration and invasion capacity of pancreatic ductal adenocarcinoma cells. This activity could be a characteristic of patients with pancreatic cancer who possess autoantibodies against  $\alpha$ -enolase (195).

Several studies analyzed the biological activities of anti-ribosomal P protein antibodies. Anti-ribosomal P protein antibodies inhibit apolipoprotein B synthesis by inducing cellular dysfunction in hepatoma cell lines. In Jurkat cells the antibodies are able to penetrate in cells and induce apoptosis (196). Other studies reported that anti-ribosomal P protein antibodies interact with several neuronal surface P antigen in hippocampal neurons, leading to impaired memory and brain cell apoptosis. Indeed, these antibodies penetrate in neuronal cells and inhibit cell proliferation through the inhibition of the activation of Erk and Akt proteins (196). We have demonstrated that the cellular stress induce an increased expression of the C-22 P0 epitope on cell membrane of pharynx cancer cell lines (132). In addition, it was reported that ectopic overexpression of P0 increases cell proliferation in breast and liver carcinoma cell lines. In our study, we demonstrated that BALB-*neuT* mice vaccinated with the human P0 protein showed a significant delay of mammary carcinoma growth and that the inhibition of tumor growth was associated with high serum levels of antibodies against P0 (133). In addition, we demonstrated the presence of a spontaneous humoral immune response to ribosomal P0 protein in colorectal cancer patients and the inhibition of *in vitro* cancer cell growth after C-22 P0 epitope targeting (134).

A recent study showed that antibodies against estrogen receptor (ER) found in patients with breast cancer, contribute to the pathogenesis of this cancer, because are able to act as estrogen agonists, leading to Erk activation and cell proliferation (143). Chernyavski *et al.* reported that patients with Phemphigus vulgaris (PV) produce antibodies that bind to AChR present on the cell membrane and on mitochondria.

The mitochondrial AChR can regulate the cytochrome *c* release by inhibiting mitochondrial permeability, leading to inhibition of the intrinsic pathway of apoptosis. In PV, this activity of mitochondrial AChR is abolished by the antibodies, leading to activation of apoptolysis (197). Autoantibodies to presynaptic P/Q-type VGCC in Lambert-Eaton myasthenic syndrome are able to block  $Ca^{2+}$  influx through voltage-gated calcium channels in SCLC cell lines, thus suggesting that *in vivo* they may interfere with tumor growth (198).

Several studies showed that anti-phospholipids autoantibodies exert different biological activities. Wu *et al.* reported that the presence of



anti-phospholipids autoantibodies is associated with invasive tumors in breast cancer patients. These autoantibodies are capable of increasing leukocyte infiltration and tumor invasion, leading to acceleration of tumor angiogenesis and progression. Anti-phospholipids autoantibodies can induce the expression of Tissue Factor (TF) and VEGF in endothelial cells and monocytes (154). In addition, it has been reported that anti-phospholipids autoantibodies are internalized into the syncytiotrophoblast and affect the inner mitochondrial membrane and alter the normal apoptotic turnover of the syncytiotrophoblast. Indeed, anti-phospholipids autoantibodies are able to increase proton leak through the inner mitochondrial membrane and to decrease the ability of the ATPase to produce ATP, leading to necrosis (199). Anti-Dsg1 and anti-Dsg3 are the main autoantibodies found in patients with PV. These autoantibodies are able to induce apoptosis through the increase of Bax, p53, Fas ligand and receptor (FasR) and activation of caspases. In addition, PV autoantibodies are able to bind to EGFR and to activate EGFR- and apoptosis (FasR)-mediated signaling pathways (200). Several studies have been demonstrated that antibodies to aquaporin-4 have the ability to diffuse in all central nervous system structures, including the optic nerve and spinal cord, and to induce oligodendrocyte death, myelin loss and neuron death. These effects are mediated by complement-dependent astrocyte cytotoxicity, through leukocyte infiltration, cytokines release and blood-brain barrier disruption (201). A recent report also demonstrated that aquaporin-4 antibodies can induce astrocytopathy, in the absence of complement activation and immune cell infiltration in Devic's neuromyelitis optica (202).

### 6. ASSOCIATION OF AUTOANTIBODIES TO SELF ANTIGENS WITH PARANEOPLASTIC AUTOIMMUNE SYNDROMES

The presence of autoantibodies to self antigens can be associated with paraneoplastic autoimmune syndromes and revealed by the occurrence of neurological syndromes as well as metabolic, rheumatic, cutaneous and haematological disorders in cancer patients due to the biological activities of the elicited immunoglobulins (40, 98, 203-228). Autoantibodies to onconeural antigens can induce in cancer patients cerebellar degeneration (anti-Hu, anti-neuronal Na<sup>(+)</sup>/K<sup>(+)</sup> ATPase, anti-ZIC4, anti-Yo, anti-CV2, anti-Tr, anti-mGluR1, Anti-Ma2, anti-Ri and anti-VGCC autoantibodies), encephalomyeloneuropathy (anti-PCA2, anti-Hu, anti-CV2, anti-Amphiphysin and anti-VGCC autoantibodies), sensory neuropathy (anti-Hu, anti-CV2 and anti-amphiphysin autoantibodies), retinopathy (anti-CV2, anti-TRMP1 and anti-Recoverin autoantibodies), DADS neuropathy (anti-MAG and anti-CENP-F autoantibodies), myasthenia gravis (anti-AchR autoantibodies), Lambert-Eaton myasthenic

syndrome (anti-SOX1 and anti-VGCC autoantibodies), neuromyelitis optica (anti-Aquaporin-4 autoantibodies), Stiff-person syndrome (anti-Amphiphysin autoantibodies) and limbic encephalitis (anti-Hu, anti-Ma2, anti-NMDAR and anti-AMPA autoantibodies) (98, 203-219). Anti-GAD autoantibodies induce paraneoplastic diabetes mellitus in SCLC or PGA2 in hepatocellular carcinoma patients (220, 221). Paraneoplastic pemphigus is characterized by the occurrence of autoantibodies to plakin family proteins in patients with haematological neoplasms, carcinomas and melanoma (222). The occurrence of anti-nuclear antibodies induces the lupus-like syndrome, the polyarteritis nodosa and the Raynaud's phenomenon in cancer patients (223). Anti-CCP autoantibodies were reported to induce polyarthritis in lung cancer patients (224). The paraneoplastic autoimmune multiorgan syndrome can arise in cancer patients for the presence of anti-platelets, anti-plectin and  $\alpha$ 2-macroglobulin-like-1 molecule autoantibodies (225, 226). Finally, anti-red cells and -platelets autoantibodies can induce autoimmune hemolytic anemia and thrombocytopenia in cancer patients, respectively (40, 227, 228). An example of the occurrence of autoantibodies in cancer patients associated with paraneoplastic autoimmune syndromes are reported in Table 3.

### 7. ROLE OF AUTOANTIBODIES TO SELF ANTIGENS AS BIOMARKERS FOR CANCER DETECTION AND CANCER PATIENTS PROGNOSIS

The presence of autoantibodies to self-antigens has been investigated as a marker for cancer detection and for predicting survival of cancer patients. Examples of these autoantibodies are reported in Table 4. Several techniques were used to discover novel tumor antigens able to elicit autoantibodies, including serological analysis of tumor antigens by recombinant cDNA expression cloning (SEREX), serological proteome analysis (SERPA), multiple affinity protein profiling (MAPPING) and high-density protein microarrays (229). However, the confirmation of the association of antibodies to tumor antigens with clinical parameters, and thus their potential use as biomarkers for early detection of cancer and cancer patients prognosis, needs validation by employing recombinant protein ELISA (Enzyme-Linked Immunosorbent Assay), protein microarrays and bead-based immunoassay (166, 229). However, the usefulness of autoantibodies as markers for cancer patients prognosis is still controversial (229). In addition, immune response to tumor antigens could also be enhanced or decreased after standard therapies. For example, we have demonstrated that radiotherapy increased the levels of autoantibodies to P0 protein and decreased those to collagens, fibronectin and HSP90 in prostate cancer patients (74). In addition, a recent study reported that the levels

**Table 3.** Pattern of autoantibodies to self antigens detected in cancer patients and associated with paraneoplastic syndromes.

| Autoantibodies   | Cancer site or histological subtype  | Paraneoplastic Autoimmune Syndromes  | References |
|--|--|--|------------|
|  |  | <b>Neurological Syndromes</b>  |            |
| Anti-PCA2  | SCLC   | Encephalomyeloneuropathy   | 208        |
| Anti-Hu (ANNA-1)   | SCLC, prostate, neuroblastoma, Hodgkin lymphoma  | Encephalomyelitis, sensory neuropathy, cerebellar ataxia, limbic encephalitis  | 98, 203    |
| Anti-neuronal Na <sup>+</sup> /K <sup>+</sup> ATPase   | Colon  | Brainstem and cerebellar syndrome  | 204        |
| Anti-ZIC4  | Ovary, SCLC  | Paraneoplastic cerebellar syndrome   | 205, 206   |
| Anti-Yo (PCA-1)  | Ovary, breast, uterus  | Paraneoplastic cerebellar degeneration   | 98, 207    |
| Anti-CV2/CRMP-5  | SCLC, thymoma  | Encephalomyeloneuropathy with corea, encephalomyelitis, sensory-motor neuropathy, uveitis, retinopathy, cerebellar ataxia                                      | 98, 208    |
| Anti-Aquaporin-4   | Lung, ovarian teratoma   | Neuromyelitis optica, longitudinally extensive transverse myelitis   | 216, 217   |
| Anti-Amphiphysin   | SCLC, breast   | Stiff-person syndrome, sensory-motor neuropathy, encephalomyelitis   | 98         |
| Anti-SOX1  | SCLC   | Lambert-Eaton myasthenic syndrome  | 215        |
| Anti-MAG   | Colon-rectum   | DADS neuropathy  | 214        |
| Anti-CENP-F  | Colon-rectum   | DADS neuropathy  | 214        |
| Anti-Ri (ANNA-2)   | SCLC, breast   | Opsoclonus-myoclonus, cerebellar ataxia  | 98         |
| Anti-Ma2 (Ta)  | Testis, lung   | Limbic-diencephalic encephalitis, subacute cerebellar degeneration, myeloradiculopathy   | 98, 210    |
| Anti-TRMP1   | Melanoma   | Retinopathy  | 212, 213   |
| Anti-Recoverin   | SCLC   | Retinopathy  | 98         |
| Anti-Tr (PCA-Tr)   | Hodgkin' disease   | Cerebellar ataxia  | 98         |
| Anti-mGluR1  | Prostate   | Cerebellar degeneration  | 209        |
| Anti-AchR  | Thymoma  | Miasthenia gravis  | 98         |
| Anti-NMDAR   | Ovarian teratoma   | Limbic Encephalitis  | 218        |
| Anti-VGCC  | SCLC, breast, lymphoma   | Encephalopathy, ataxia, myelopathy, neuropathy, neuromuscular junction disorder, myopathy, Lambert-Eaton myasthenic syndrome, subacute cerebellar degeneration | 98, 211    |
| Anti-AMPAR   | Breast   | Limbic encephalitis  | 219        |
|  |  | <b>Metabolic Syndromes</b>   |            |
| Anti-GAD   | SCLC, HCC  | Diabetes mellitus, PGA2  | 220, 221   |
|  |  | <b>Skin and Mucous Membrane Syndromes</b>  |            |
| Anti-Plakin family proteins (desmoplakins I and II, BP230, periplakin, Envoplakin, Dsg-3 and/or Dsg-1) | Haematological neoplasms, carcinomas and melanoma  | Pemphigus  | 222        |
| Anti-Plakins, Anti-Plectin, $\alpha$ 2-macroglobulin-like-1 molecule                                   | NHL, CLL, Castleman disease, pancreas, colon, breast, prostate, liver, tongue, bronchi, cervix, kidney | Paraneoplastic autoimmune multiorgan syndrome  | 225, 226   |
|  |  | <b>Rheumatic Syndromes</b>   |            |
| Anti-CCP   | Lung   | Polyarthritis  | 224        |
| ACA, ANA   | Liver, ovary, testis, kidney, melanoma, lymphoma, multiple myeloma                                     | Raynaud's phenomenon   | 223        |
| ANA  | Ovary, breast, head and neck, meningioma   | Lupus-like syndrome  | 223        |
| ANCA   | Kidney, colon  | ANCA-associated vasculitis   | 223        |

## Autoantibodies to self antigens in cancer patients

|  |  |                                |          |
|--|--|--------------------------------|----------|
| ANA  | Stomach, lung angiomatoid fibrous histiocytoma | Polyarteritis nodosa           | 223      |
|  |  | <b>Hematological Syndromes</b> |          |
| Anti-red cells                             | B cell lymphoma, colon, leukemia, kidney       | AIHA                           | 227, 228 |
| Anti-phospholipids, platelet glycoproteins | Lymphoproliferative disease                    | AITP                           | 228      |

PCA: Purkinje cell cytoplasmic antibody; SCLC: Small cell lung cancer; ANNA: Anti-neuronal nuclear antibody; ZIC4: Zinc finger protein of cerebellum; CV2/CRMP-5: Collapsin response-mediator protein-5; MAG: Myelin-associated glycoprotein; DADS: Distal acquired demyelinating symmetric; CENP-F: Centromere nuclear protein-F; TRMP1: transient receptor potential cation channel, subfamily M, member 1; mGluR1: Metabotropic glutamate receptor type 1; AchR: Acetylcholine receptor; NMDAR: N-methyl-D-aspartate receptor; VGCC: Voltage-gated calcium channels; AMPAR: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; GAD: Glutamic acid decarboxylase; HCC: Hepatocellular carcinoma; PGA2: Polyglandular autoimmune syndrome type 2; Dsg: Desmoglein; NHL: Non Hodgkin lymphoma; CCP: Cyclic citrullinated peptide; ACA: Anti-centromere antibody; ANA: Anti-nuclear antibodies; ANCA: Anti-neutrophil cytoplasmic antibodies; AIHA: Autoimmune hemolytic anemia, AITP: Autoimmune thrombocytopenia.

**Table 4.** Examples of autoantibodies to self antigens proposed as biomarkers or associated with cancer patients prognosis.

| Type of tumor | Autoantibodies  | Signature of cancer as compared to control groups or prevalence | Survival or Prognosis or Recurrences          | References    |
|---------------|---|---|---|---------------|
| Breast cancer | Anti-P0   | Significant (Prevalence of 10.6%)                               | No correlation with clinical stage            | 133           |
|               | Anti-Annexin XI-A, -Ku, -Ribosomal protein S6   | Significant   | NA  | 231           |
|               | Anti-MUC-1 glycoforms   | Significant   | Lower incidence of metastases                 | 232           |
|               | Anti-CENP-B   | Significant (Prevalence of 33%)                                 | Longer DFS and OS                             | 233           |
|               | Anti-p53  | Significant   | Shorter 5-year survival                       | 234           |
|               | Anti-p53  | Prevalence of 9%  | Shorter survival                              | 235           |
|               | Anti-SOX2   | Significant (Prevalence of 18.4%)                               | NA  | 236           |
|               | Anti-FKBP52, -PPIA, -PRDX2  | Significant   | NA  | 237           |
|               | Anti-PARP1, -BRCA2  | Significant (Prevalence of 15.3% and 36.6% respectively)        | NA  | 238           |
|               | Anti-HER2, -p53, -CEA, -Cyclin-B1   | Significant   | NA  | 239           |
|               | Anti-EPHA2, -IGFBP2, -CST2, -GAL1, -HER-2, -LAMC2, -ANGPTL4, -DKK1, -MUC1, -SSR2, -SPINT2, -SPON2 | Significant   | NA  | 240           |
|               | Anti-c-Myc, -Survivin, -Cyclin-B1, -Cyclin-D1, -p62, -p53, -p16, -CDK2                            | Significant (Sensitivity of 61%, specificity of 89%)            | NA  | 241           |
|               | Anti-Imp1, -p16, -Koc, -Survivin, -Cyclin-B1, -c-Myc  | Significant (Sensitivity of 67.3%, specificity of 92.2%)        | NA  | 242           |
|               | Anti-p90/CIP2A  | Significant   | NA  | 242           |
| Anti-IMP2/p62 | Significant (Prevalence of 14.3%)   | NA  | 242   |               |
|               | Anti-MDM2, -c-Myc   | Significant   | Shorter DFS (anti-c-Myc)                      | 33            |
|               | Anti-HuC or -HuD  | Significant (Prevalence of 23.3%)                               | NA  | 96            |
|               | Anti-p53  | Significant (Prevalence of 20.6%)                               | Poor prognosis                                | 244           |
|               | Anti-p53  | Significant   | No association with survival or disease stage | 245, 246, 247 |
|               | Anti-ANXA1  | Significant (Sensitivity of 23%, specificity of 90%)            | NA  | 248           |
|               | Anti-CCNY   | Significant (Sensitivity of 23.5%, specificity of 95.5%)        | Poor prognosis                                | 249           |
|               | Anti-IGFBP-2  | Significant (Sensitivity of 73.2%, specificity of 90%)          | NA  | 250           |
|               | Anti-p16  | Significant (Sensitivity of 19.7%, specificity of 60.6%)        | Association with advanced stage               | 251           |
|               | Anti-Chromogranin A   | Significant (Sensitivity of 47.6%, specificity of 80.0%)        | NA  | 252           |

**Autoantibodies to self antigens in cancer patients**

|                          |  |   |                                      |     |
|--------------------------|--|---|--------------------------------------|-----|
| Lung cancer              | Anti-SMOX, -NOLC1, -MALAT1, -HMMR  | Significant (Sensitivity of 47.5%, specificity of 97.3%)    | NA                                   | 253 |
|                          | Anti-NY-ESO-1, -XAGE-1, -ADAM29, -MAGEC1   | Significant (Sensitivity of 33%, specificity values of 96%) | Association with advanced stage      | 254 |
|                          | Anti-p53, -NY-ESO-1, -CAGE, -SOX2, -GBU4-5, -Annexin 1   | Significant (Sensitivity of 34%, specificity of 91%)        | No differences between disease stage | 255 |
|                          | Anti-14-3-3 $\zeta$ , -c-Myc, -MDM2, -p16, -p53, -Nucleophosmin, -Cyclin-B1  | Significant (Sensitivity of 68.9%, specificity of 79.5%)    | NA                                   | 256 |
|                          | Anti-KIAA037, -ROCK1, -PRKCB1, -TACC2, -C14ORF145, -ARFGAP3, -YBX1, -SOX2 homologous   | Significant (Prevalence of 15%)                             | NA                                   | 257 |
|                          | Anti-monophosphate dehydrogenase, -fumarate hydratase, - $\alpha$ -enolase, endoplasmic reticulum protein 29, -Annexin 1, -hydrosteroid 17- $\beta$ dehydrogenase, -MTAP | Significant   | NA                                   | 258 |
|                          | Anti-TTC14, -BRAF, -CTAG1B, -ACTL6B, -MORC2  | Significant   | NA                                   | 259 |
|                          | Anti-p62, -BIRC, -Livin-1, -p53, -PRDX, -NY-ESO-1, -Ubiquitin  | Significant   | NA                                   | 260 |
|                          | Anti-p53   | NA  | Lower probability of OS and DFS      | 262 |
|                          | Anti-p53   | NA  | No association with survival         | 265 |
| Esophagus cancer         | Anti-CD25  | Significant   | NA                                   | 266 |
|                          | Anti-FOXP3   | Significant (Sensitivity of 22.7%, specificity of 95%)      | NA                                   | 267 |
|                          | Anti-p16   | Significant (Prevalence of 5.7%)                            | NA                                   | 268 |
|                          | Anti-c-Myc, -HCCR, -p53, -p62  | Significant   | NA                                   | 269 |
| Gastric cancer           | Anti-p53   | Significant   | Longer survival                      | 270 |
|                          | Anti-p53   | Prevalence of 20.3%   | Poor prognosis                       | 271 |
|                          | Anti-p53   | Prevalence of 31%   | NA                                   | 272 |
|                          | Anti-p53   | Prevalence of 12.2%   | Shorter survival                     | 273 |
|                          | Anti-GRP78   | Prevalence of 28.3%   | NA                                   | 274 |
|                          | Anti-MAGEA4, -CTAG1, -p53, -ErbB2_C, -SDCCAG8  | Significant   | NA                                   | 275 |
|                          | Anti-p53, -Koc, -p62, -c-Myc, -IMP1, -Survivin, -p16   | Prevalence of 64%   | NA                                   | 276 |
|                          | Anti-CT antigens (-MAGEC1, -MAGEA3, -CTAG2, -CTAG1B)   | Significant   | NA                                   | 277 |
| Colorectal cancer        | Anti-dsDNA   | Significant   | Less incidence of recurrences        | 10  |
|                          | Anti-p53   | Significant   | No association with survival         | 31  |
|                          | Anti-P proteins  | Significant (Prevalence of 10.4%)                           | NA                                   | 134 |
|                          | Anti-p53   | Prevalence of 25%   | Shorter survival                     | 278 |
|                          | Anti-PIM1, -MAPKAPK3, -ACVR2B  | Significant (Sensitivity of 84.1%, specificity of 71.4%)    | NA                                   | 279 |
| Hepatocellular carcinoma | Anti-Nucleophosmin 1   | Significant (Prevalence 24.4%)                              | NA                                   | 26  |
|                          | Anti-c-Myc, -p53, -Cyclin-B1, -p62, -Koc, -IMP, -Survivin  | Significant (Prevalence of 59.9%)                           | NA                                   | 42  |
|                          | Anti-p53   | Significant   | Shorter survival                     | 280 |
|                          | Anti-p53   | Significant   | NA                                   | 281 |
|                          | Anti-Sui1, -RalA   | Significant (Prevalence of 11.7% and 19.5%, respectively)   | NA                                   | 282 |
|                          | Anti-DDX3, -eEF2, -AIF, -hnRNP A2, -PBP, -TIM  | Significant   | NA                                   | 283 |

**Autoantibodies to self antigens in cancer patients**

|   |   |  |   |          |
|---|---|--|---|----------|
|   | Anti-AFP, -Gankyrin, -GPC-3, -IMP1, -p62, -Koc, -p53, -c-Myc, -Cyclin-B1, -HuD, -Survivin, -MAGEA4, -p16, -SOX-2, -CAGE, -NY-ESO-1, -GBU4-5 | 21 TAAs (Specificity 92%, sensitivity 45%; high risk positivity 21%)   | NA  | 284      |
|   | Anti-p53  | NA   | Shorter survival                                | 285      |
|   | Anti-p53  | Prevalence of 7%   | Higher survival rate without recurrence         | 286      |
|   | Anti-AFP  | Significant  | NA  | 287, 288 |
| Pancreatic cancer                                     | Anti-DDX48  | Significant (Prevalence of 33.33%)   | NA  | 289      |
| Ovarian cancer  | Anti-IMP, -IMP2/p62   | Significant (Prevalence of 26.5% and 29.4% respectively)   | NA  | 43       |
|   | Anti-PARP1, - BRCA1   | Significant (Prevalence of 29.4% and 50.0% respectively)   | NA  | 238      |
|   | Anti-p53  | Prevalence of 15%  | No association with OS                          | 290      |
|   | Anti-p53  | Prevalence of 25% (serum) and of 19% (ascites)   | Unfavorable DFS and OS (Ascites autoantibodies) | 291      |
|   | Anti-p53  | Significant  | Improved OS                                     | 292      |
|   | Anti-p53  | Prevalence of 12.4%  | No association with survival                    | 293      |
|   | Anti-p53  | Prevalence of 19%  | Shorter OS and DFS                              | 294      |
|   | Anti-CFL1, -EZR, -JUP, -HIST1H1C, -HNRNPAB, -HSPA9, -PDZD11, -PFN1, -PP1A, -SERF2, -TUBA1C  | Significant  | NA  | 295      |
|   | Anti-p53, -PTGFR, -PTPRA, -ACSBG1, -AFP, -CSNK1A1L, -DHFR, -PRL, -PSMC1, -RAB7L1, -SCYL3  | Significant  | NA  | 296      |
| Anti-p53  | NA  | No association with OS (pooled uni-multivariate HRs). Association with a better OS with a pooled multivariate HRs (4 studies)          | 297   |          |
| Prostate cancer                                       | Anti-protein biosynthesis, -translation, -cytoskeleton, -nucleus and organelles   | Significant  | NA  | 298      |
|   | Anti -60S ribosomal protein L7, -MARCKS1 homologous   | Significant (discrimination between prostate cancer patients and patients with prostatic benign hyperplasia)                           | NA  | 299      |
|   | Anti-MUT, -RAB11B, -CSR2, -SPOP, -ZNF671  | Discrimination between prostate cancer patients with low from those with high inflammation (Sensitivity of 80% and specificity of 67%) | NA  | 300      |
| Pediatric ALK-positive anaplastic large cell lymphoma | Anti-ALK  | Prevalence of 38%  | Lower incidence of relapse                      | 301      |

NA: Not Available; MUC: mucin; CENP-B: centromere nuclear protein-B; DFS: disease-free survival; OS: overall survival; FKBP: FK506 binding protein; PPIA: Peptidylprolyl isomerase A; PRDX: peroxiredoxin; PARP1: Poly(ADP-ribose) polymerase 1; BRCA2: Breast related cancer antigen 2; HER2: Receptor tyrosine-protein kinase erbB-2; CEA: carcinoembryonic antigen; EPHA2: Ephrin type-A receptor 2; IGFBP2: Insulin-like growth factor-binding protein 2; CST2: Cystatin-SA; GAL1: Galactokinase 1; LAMC2: Laminin subunit gamma 2; ANGPTL4: Angiopoietin-like 4; DKK1: Dickkopf-related protein 1; SSR2: serine-rich repeat protein 2; SPINT2: Kunitz type serine peptidase inhibitor 2; SPON2: spondin 2; p90/CIP2A: cancerous inhibitor of PP2A; IMP2/p62: IGF2 mRNA-binding protein 2; CCNY: Cyclin Y; SMOX: spermine oxidase; NOLC1: Nucleolar and coiled-body phosphoprotein 1; MALAT1: Metastasis-associated lung adenocarcinoma transcript 1; HMMR: Hyaluronan mediated motility receptor; XAGE-1: X antigen family member-1; ADAM29: ADAM metalloproteinase domain 29; MAGEC1: MAGE family member C1; CAGE: Cancer-associated gene; ROCK1: Rho-associated, coiled-coil-containing protein kinase 1; PRKCB1: Protein kinase C beta 1; TACC2: Transforming acidic coiled-coil-containing protein 2; C14ORF145: Human centrosomal protein of 128 kDa; ARFGAP3: ADP-ribosylation factor GTPase activating protein 3; YBX1: Y box binding protein 1; MTAP: Methylthioadenosine phosphorylase; TTC14: tetratricopeptide repeat domain 14; BRAF: B-Raf proto-oncogene, serine/threonine kinase; ACTL6B: Actin like 6B; MORC2: MORC family CW-type zinc finger 2; CTAG1: cancer/testis antigen 1; BIRC: Baculoviral inhibitors of apoptosis repeat containing; CD25: Alpha chain of the IL-2 receptor; FOXP3: Forkhead box P3; GRP78: Glucose-regulated protein 78; SDCCAG8: Serologically defined colon cancer antigen 8; dsDNA: Double-strand DNA; MAPKAPK3: MAP kinase-activated protein kinase 3; ACVR2B: Activin receptor type-2B; RalA: Ras-related protein Ral-A; DDX: DEAD-box protein; eEF2: Eukaryotic elongation factor 2; AIF: Apoptosis-inducing factor; hnRNP: Heterogeneous nuclear ribonucleoprotein; PBP: Prostatic binding protein; TIM: T-cell immunoglobulin and mucin-domain; AFP: Alpha-fetoprotein; GPC-3: Glypican-3; CFL1: Cofilin 1; EZR: Ezrin; HIST1H1C: Histone cluster 1 H1 family member C; HSPA9: Heat shock protein family A (Hsp70) member 9; PDZD11: PDZ domain-containing protein 11; PFN1: Profilin-1; PP1A: Protein phosphatase 1A; SERF2: Small EDRK-rich factor 2; TUBA1C: Tubulin alpha 1C; JUP: Junction plakoglobin; PTGFR: Prostaglandin F receptor; PTPRA: Protein tyrosine phosphatase, receptor type A; ACSBG1: Acyl-CoA synthetase bubblegum family member 1; CSNK1A1L: Casein kinase 1 alpha 1 like; DHFR: Dihydrofolate reductase; PRL: Prolactin; PSMC1: Proteasome 26S subunit, ATPase 1; HR: Hazard ratio; MUT: Methylmalonyl-CoA mutase; CSR2: Cysteine and glycine-rich protein 2; SPOP: Speckle-type POZ protein; ZNF671: Zinc finger protein 671; ALK: Anaplastic lymphoma kinase.

## Autoantibodies to self antigens in cancer patients

of autoantibodies against galectin-3 could be useful to predict the efficacy of chemotherapy in patients with lung adenocarcinoma (230).

Autoantibodies to a single antigen including p53, CENP-B, annexin XI-A, the p80 subunit of the Ku antigen, ribosomal protein S6, ribosomal P0 protein, p90/CIP2A, SOX2, IMP2/p62 and glycoforms of MUC1 could significantly discriminate breast cancer patients from healthy donors (26, 133, 231-236). To improve cancer detection, recent studies have analyzed the presence of autoantibodies to a panel of antigens. For example autoantibodies to FKBP52, PPIA, and PRDX2, to PARP1 and BRCA1/BRCA2 or to HER2, p53, CEA, and cyclin-B1 were significantly detected in cancer patients as compared to healthy controls (237-239). Overall a combination of autoantibodies against different antigens allowed to discriminate cancer patients from healthy donors and autoantibodies to HER2 and p53 could be detected in prediagnostic cancer patient sera (239-242). Anti-p53 autoantibodies were associated with a shorter patients survival (234, 235). Conversely, the presence of anti-CENP-B autoantibodies was associated with prolonged DFS and OS, and that to MUC1 glycoforms to a lower incidence of metastases and increased time to metastasis (232, 233).

Several studies have demonstrated the presence of significant levels of autoantibodies in lung cancer patients as compared to healthy donors (33, 96, 243-265). Circulating autoantibodies to individual p53, annexin A1-derived peptide antigens, CCNY, IGFBP-2, p16, chromogranin A-derived peptides were significantly higher in cancer patients than control subjects (243-252). Autoantibodies to two or more antigens including HuC/HuD, SMOX/NOLC1/MALAT1 and HMMR, NY-ESO-1/XAGE-1/ADAM29, and MAGEC1, p53/NY-ESO-1/CAGE, GBU4-5/Annexin 1 and SOX2, 14-3-3 $\zeta$ -c-Myc/MDM2/Nucleophosmin 1/p16/p53 and cyclin-B1, p62/BIRC/Livin-1/p53/Peroxiredoxin/NY-ESO-1 and Ubiquitin, and several other antigens combination were analyzed for improving the sensitivity and specificity of the assays for discriminating cancer patients from healthy donors (33, 96, 253-260). In addition, autoantibodies to p16, NY-ESO-1, XAGE-1, ADAM29, and MAGEC1 were associated with advanced disease stages, those to c-Myc were related to shortened DFS and those to p53 or to CCNY were linked to shorter survival or worse prognosis (33, 243, 244, 249, 251, 254, 261, 262). Conversely, ANAs were linked to a better patients survival (263). Other reports detecting autoantibodies to p53 could not reveal any association with patients survival or disease stage (245-247, 255, 264, 265).

Serum of patients with digestive tract tumors was analyzed for the presence of autoantibodies

to self antigens too (266-277). The prevalence of autoantibodies to CD25, or FOXP3, or p16 was significantly higher in esophageal squamous cell carcinoma patients than in the control groups (266-268). In addition, autoantibodies to a panel of four antigens (c-Myc, HCCR, p53 and p62) showed high diagnostic accuracy for esophageal cancer (269). Autoantibodies to p53 or GRP78 were detected with higher prevalence in gastric carcinoma patients than in healthy donors (270-274). The survival time of gastric carcinoma patients testing positive for anti-p53 autoantibodies was significantly longer than that of testing negative patients (270). However, p53 autoantibodies were predictor of an unfavorable prognosis in other studies (271, 273). Combination of autoantibodies against five tumor-associated antigens (TAAs) (MAGEA4 + CTAG1 + TP53 + ERBB2\_C + SDCCAG8) was able to increase the percentage of positive gastric cancer patients (275). In the study performed by Zhou *et al.*, the sensitivity and the specificity for autoantibodies against seven TAAs (Anti-p53, -Koc, -p62, -c-Myc, -IMP1, -Survivin and -p16) in diagnosing gastric cardia adenocarcinoma reached up to 64% and 87%, respectively (276). By applying a T7 phage display-based serological analysis of recombinant cDNA expression libraries technique it was identified a representative set of antigens eliciting humoral responses in gastric cancer patients. 45-autoantibodies signature could discriminate gastric cancer patients from healthy donors (277).

The prevalence of autoantibodies to dsDNA or p53 or P proteins were higher in patients with colorectal cancer than in healthy subjects (10, 31, 134, 278). The prevalence of simultaneous autoantibodies to PIM1, MAPKAPK3, and ACVR2B were able to discriminate between colorectal cancer and control samples with a sensitivity of 84.1% and a specificity of 71.4% (279). No correlation was found between colorectal cancer patients survival and anti-p53 autoantibodies (31). Conversely, in another study a shorter survival characterized patients positive for anti-p53 autoantibodies (278). In addition, patients with anti-dsDNA autoantibodies showed a less incidence of recurrences after a 3-year follow-up (10).

The prevalence of autoantibodies against p53, or, nucleophosmin was higher in HCC patients than that in healthy donors (26, 280, 281). Autoantibodies to multiple tumor-associated antigens were shown to enhance detection of HCC showing higher prevalence in HCC patients than in chronic hepatitis and normal donor sera (42, 282-284). A shorter patients survival time was observed in HCC patients displaying anti-p53 autoantibodies (280, 285). On the other hand, a study reported that HCC patients having anti-p53 autoantibodies had higher survival rate without recurrence (286). In addition, autoantibodies to  $\alpha$ -fetoprotein were more prevalent in HCC patients



than in healthy donors or liver cirrhosis and chronic hepatitis patients (287, 288).

Reactivity to DDX48 was observed in 20 of 60 (33.33%) pancreatic cancer patients while none of the 60 normal individuals analyzed had anti-DDX48 autoantibodies (289).

The high prevalence of autoantibodies to p53, IMP1 and IMP2/p62, PARP1 and BRCA1, or to a panel of different antigens suggested that autoantibodies could be potential biomarkers in immunodiagnosis of ovarian cancer (43, 238, 290-296). However, there is not an agreement for the prognostic value of anti-p53 autoantibodies. Shortened OS and RFS or unfavorable DSF and OS were reported in ovarian cancer patients harboring serum or ascites anti-p53 autoantibodies, respectively (291, 294). Conversely, one study reported that anti-p53-autoantibodies were prognostic for improved OS (292). Other studies reported no association with patients survival (290, 293). Finally, the presence of anti-p53 autoantibodies was significantly associated to a better OS when only multivariate HRs were pooled together (4 studies) (297).

Autoantibodies to multiple antigens were detected in prostate cancer patients (298-300). Massoner *et al.* found autoantibodies to 408 different antigens and reported that 174 of these were solely detected in cancer patients compared to healthy donors (298). Autoantibodies to antigens fragments with homology to 60S ribosomal protein L7, and MARCKS1 were able to discriminate prostate cancer patients from patients with benign prostatic hyperplasia (299). The presence of autoantibodies to MUT, RAB11B, CSRP2, SPOP and ZNF671 was able to distinguish prostate cancer patients with low from those with high inflammation with a sensitivity of 80% and a diagnostic specificity of 67% (300). None of these studies investigated the prognostic values of autoantibodies.

Finally, high antibody titers to ALK (prevalence 38%) correlated with significantly lower cumulative incidence of relapses in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (301).

## **8. PARANEOPLASTIC NEUROLOGICAL SYNDROMES, EFFECTS OF THERAPY TARGETING IMMUNE-CHECKPOINT RECEPTORS AND Tregs DYSREGULATION IN AUTOIMMUNE DISEASE PATIENTS: THE CROSSROAD BETWEEN AUTOIMMUNITY AND IMMUNE RESPONSE IN CANCER PATIENTS**

From studies regarding patients with paraneoplastic neurological syndromes we have

learned that antibodies to self antigens might reflect the attempt to counteract tumor growth and might affect cancer patients survival (302, 303). Patients survival analysis showed a significantly shorter median survival time from the diagnosis of SCLC in SCLC patients without Lambert-Eaton myasthenic syndrome than in those with Lambert-Eaton myasthenic syndrome (304). Dalmau *et al.* analyzed 71 patients with “paraneoplastic” encephalomyelitis or sensory neuronopathy, or both who had serum anti-Hu antibodies. Most of the patients (78%) had small-cell lung cancer. In 9 patients no tumor was revealed. Thus, the authors searched for the presence of the tumor that when detected was frequently small and localized or was detected only at autopsy (305). Peterson *et al.* reviewed the clinical findings in 55 patients with cerebellar degeneration associated with the anti-Yo autoantibodies. Fifty-two of them had cancers, mainly limited to the involved organs (breast and gynecological tract) and local lymph nodes. One woman had lung adenocarcinoma, and in three no malignancy was identified. In 34 of 52 patients with cancer, the neurologic syndrome preceded the cancer diagnosis and in many led to the diagnosis (306). Graus *et al.* found that the presence of anti-Hu autoantibodies in patients with paraneoplastic encephalomyelitis/sensory neuropathy and SCLC is a strong and independent predictor of complete response to the therapy and that this feature accounts for the association between anti-Hu autoantibodies and longer cancer patients survival (307). Honnorat *et al.* found that the median survival time was significantly longer in patients with SCLC and anti-CV2/CRMP5 autoantibodies as compared to patients with SCLC and anti-Hu autoantibodies, thus suggesting that the prognosis of the same type of tumor may be dependent on the type of onconeural autoantibodies (308). Hetzel *et al.* suggested that the immune response evoked against cancer cells and probably cross-reactive with cerebellar cells, might affect the metastatic process. Indeed, the authors found that in 8 patients who had primary stage III gynecological cancer and anti-Purkinje cell autoantibodies as compared to 24 control patients without paraneoplastic cerebellar degeneration there was no difference in the volume of the primary tumor but a significantly smaller volume of the metastatic tumor in the autoantibodies-positive group (309). In a prospective analysis of the presence of self-antigens autoantibodies and of mortality in 238 SCLC patients, Gozzard *et al.*, observed an independent survival advantage associated with anti-neuronal nuclear antibodies (ANNAs) (310). On the other hand, Rojas *et al.* by retrospectively analyzing the clinical outcome and prognostic factors in a series of 34 patients with paraneoplastic cerebellar degeneration and anti-Yo autoantibodies found that the overall prognosis of cancer patients was rather poor, particularly for patients with gynecologic tumors (311). In addition, in some reports tumor was shown to regress in patients

with paraneoplastic neurological degeneration (303). Zaheer *et al.* described a case of small SCLC that spontaneously regressed in concomitant with the occurrence of a paraneoplastic neurological syndrome and the presence of anti-neuronal antibodies (312). Darnell described a spontaneous regression of a lung mass in a patient with both the anti-Hu and atypical anti-neuronal antibodies and subacute sensory neuropathy (302). In addition they found that one patient survived 8 years free of disease and was positive for the anti-Hu autoantibodies and another patient survived 6 years after spontaneous tumor regression and had anti-neuronal autoantibodies (302). Mawhinney *et al.* reported that a paraneoplastic sensory neuropathy with high titers of anti-Hu autoantibodies, was associated with lung tumor regression (313). Similarly, Gill *et al.* reported a case of a patient with anti-Hu autoantibodies associated paraneoplastic sensory neuronopathy who had a spontaneous regression of the small cell lung cancer (314). Hirano *et al.* observed a partial spontaneous regression of a SCLC tumor associated with a progression of paraneoplastic sensory neuropathy and the presence of anti-neuronal autoantibodies in a 55-year-old woman (315). Villers *et al.* reported a paraneoplastic amyopathic dermatomyositis associated with the regression of a primary melanoma (316).

The microenvironment within the tumor can support the growth of cancer cells through the release of growth factors and immunosuppressive cytokines by endothelial cells, immune cells and mesenchymal stromal cells (MSC) (317). Among the others, Tregs are key regulators of the immune responses, avoiding abnormal immune system activation and autoimmunity (318). Tregs have shown to suppress the activity of effector T cells, Natural Killer (NK) cells and dendritic cells either by cell-cell contact or by the secretion of immunosuppressive cytokines (IL-10 and TGF $\beta$ ) and indoleamine-2,3-dioxygenase (IDO) (318). On the other hand, MDSCs stimulate chronic tissue inflammation and suppression of immune response by the release of reactive oxygen species, nitric oxide, arginase-1 and cytokines and by the recruitment and induction of Tregs and immunosuppressive tumor-associated macrophages (TAM) in the tumor microenvironment (318). Several inhibitory pathways are involved in maintaining immune self-tolerance thus preventing autoimmune diseases and exaggerate immune responses to pathogens (319). The occurrence of an autoimmune disease is a sign of a merged deficiency of both central and peripheral immune tolerance inducing the activation of autoreactive T cells (5). Tregs express immune-checkpoint receptors, including cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1), T cell membrane protein 3 (TIM3), adenosine A2a receptor (A2aR), lymphocyte activation gene 3 (LAG3) that are essential for the development of self-tolerance (319). In

addition, the negative regulatory checkpoint receptors can be dysregulated by cancer cells to suppress anti-tumor activity of immune response (319). CTLA4 regulates the magnitude of T cells activation during the initial stage of the immune response. Indeed, CTLA4 expression on the membrane of T cells reduces their activation by competing with CD28 in the binding with B7.1 and B7.2 in addition to provide inhibitory signals to T cells, thus activating the immune suppressive functions of Tregs (319). On the other hand, PD1 reduces the activation of T cells in peripheral tissue by directly interfering with T cell receptor signaling and restricts autoimmune phenomena (320). Cancer cells expressing PD1 ligands (PDL1 and PDL2) lead to T cells exhaustion or anergy (319, 320). In addition, PD1 is expressed by B and NK cells (321). The upregulation of PD1 ligands on cancer cells may be constitutive due to tumor cells abnormal signaling pathways activation and may lead to innate immune resistance or may mirror cancer cells adaptation to the anti-tumor response thus leading to adaptive immune resistance (319). Accordingly, CTLA4 (ipilimumab), PD1 (nivolumab and pembrolizumab) and PD-L1 antibodies were employed in clinical trials in patients with a variety of tumor types showing a clinical response (321, 322). Of note, two phase III clinical trials employing the ipilimumab have shown improved survival of patients with advanced melanoma (321). Nivolumab treatment of metastatic melanoma patients induced an objective response rate of 40% and overall survival rate of 72.9% as compared to an objective response rate of 13.9% and overall survival rate of 42.1% obtained with dacarbazine chemotherapy (321). Since the mechanisms of CTLA4 and PD1 are distinct, combined treatment with both antibodies CTLA4 and PD1 were employed (321). A Phase I clinical trial conducted in patients with advanced melanoma, showed that concurrent therapy with nivolumab and ipilimumab induced rapid and deep tumor regression in a substantial proportion of patients which appears to be distinct from that observed employing single therapy (323). Recently an anti-PDL1 monoclonal antibody, avelumab, was proven to block PD1/PDL1 interaction, to mediate ADCC of cancer cells (324). In addition, a phase I study reported its non toxicity (324).

Other clinical trials are ongoing to evaluate the efficacy of combination therapies by using anti-CTLA4 or anti-PD1 antibodies and epacadostat, an IDO1 enzyme inhibitor. Indeed, IDO1 is an intracellular immunoregulatory enzyme involved in tumor escape, tolerance and immunosuppression. IDO-expression has been identified as a prognostic marker of survival in several cancers and IDO upregulation is a critical mechanism of resistance to anti-cancer immunotherapy with CTLA4 antibodies. It has been recently demonstrated that epacadostat was able to increase dendritic cells antigen presentation, to

decrease Tregs proliferation and to increase CTLs activity. Thus the combined therapies by using an inhibitor of IDO1 represent a promising strategy in cancer immunotherapy (325).

On the other hand, the blockade of immune-checkpoint receptors by antibodies induces inflammatory adverse effects that mimic an autoimmune response (320). A patient with advanced mucosal melanoma who received four doses of a fully human monoclonal antibody against PD1 (MK-3475) had a durable near-complete response but developed severe hypothyroidism, rhabdomyolysis, and acute kidney injury (326). Therapy with a combination of ipilimumab and nivolumab, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis in melanoma patients (327). Michot *et al.* reviewed the immune-related adverse events (IRAE) found in cancer patient after immune-checkpoint receptors blockade (328). The authors reported that skin immune-related event especially vitiligo is the most frequent IRAE after blockade of the immune-checkpoint receptors in patients with melanoma. Other dermatological reactions encompassed rash/erythema and toxic epidermal necrosis (328). A small percentage (5%) of patients declared dry mouth and showed the presence of ANAs. Diarrhoea was developed in about 30% of the patients after anti-CTLA4 therapy while colitis after the same treatment resembled the characteristic of Crohn's disease. In addition, by reviewing the literature they found that some patients (5-10%) receiving antibodies to immune-checkpoint receptor developed endocrine diseases such as thyroid dysfunction and hypophysitis for a deficient release of ACTH, TSH, FSH, LH, growth hormone or prolactin (328). IRAE might be also characterized by autoimmune hepatitis, immune-related- and organizing inflammatory-pneumonitis. Ophthalmological IRAEs (episcleritis, conjunctivitis, uveitis, etc) and neurological syndromes (posterior reversible encephalopathy, transverse myelitis, Guillan Barré syndrome, etc) have been described in patients receiving anti-CTLA4 antibodies (328). The presence of ANAs and anti-CCP autoantibodies characterized IRAE such as polyarthritis in patients after anti-CTLA4 therapy. Renal and pancreatic disorders were also seen in a small percentage of CTLA4 and PD1 antibodies-treated patients. Finally, hematological disorders including autoimmune neutropenia or pancytopenia, red cells aplasia have been described after patients anti-CTLA4 therapy (328). The authors concluded that the dysimmune toxicity might be associated with the antitumor response in cancer patients (328).

The value of Tregs dysfunction in generating an immune response has been consolidated in patients with paraneoplastic syndromes while the increase of Tregs has been associated with poor

prognosis in cancer patients (329). Zhang *et al.* reported that patients with paraneoplastic neurological syndrome, anti-Hu autoantibodies and SCLC showed lymphopenia of CD3+ and CD4+ T cells, increased proportions of total activated T cells and activated CD4+ T cells, and reduced numbers of Tregs (329). Tani *et al.* found that the expression levels of FOXP3, TGF- $\beta$  and CTLA4 mRNA in Treg-rich subsets of paraneoplastic neurological syndrome patients were down-regulated compared with that of SCLC patients without paraneoplastic neurological syndrome (330). Wang *et al.* showed that Treg infiltration was an indicator of a poorer prognosis for breast cancer patients (331). Higher Tregs frequencies were observed in early phase of bladder cancer growth and in larger tumors with more aggressive type of invasion (332). A strong immunosuppressive microenvironment in metastatic lymph nodes from patients with cervical cancer with high Tregs levels, low CD8+ T cell/Tregs ratio, and high levels of PD-L1+ and HLA-DR+ myeloid cells was reported by Heeren *et al.* (333). Therefore, immune suppression through Tregs or other types of suppressive cells resident within the tumor microenvironment, appears to be a major mechanism of tumor immune escape (334).

The association between autoimmunity, immune response to self antigens in cancer patients and anti-tumor effects obtained targeting Tregs in cancer patients is disclosed by the dysfunction of Tregs observed in patients developing autoimmune diseases (335). Tregs dysfunctions including loss of Foxp3 expression (exTreg), self-skewed TCR repertoire and atypical Treg functions including the expression of vascular endothelial growth factor or expression of RANKL have been shown to turn in pathogenic Tregs in several disease models (335). The alteration of Tregs is a key pathogenic occurrence which induces a multi-organ autoimmunity that characterizes the immune dysregulation, polyendocrinopathy, enteropathy and X-linked (IPEX) syndrome (336). Tregs alterations may lead to melanocyte loss in vitiligo, rheumatoid arthritis, type 1 diabetes and autoimmune thyroiditis (337-340) (Figure 1).

In view of all these findings, the biological activity of antibodies observed in cancer patients showing paraneoplastic syndrome might resemble the activation of immune response in cancer patients in the absence of immunosuppression. Indeed, the IRAE observed after immune-checkpoint receptors antibodies therapy might reflect a humoral and cell-mediated antitumor response.

## 9. CONCLUSIONS

Several studies have shown that cancer patients develop autoantibodies to self antigens with higher prevalence than healthy donor or patients




Figure 1. Disfunction of Tregs in autoimmune diseases, paraneoplastic syndromes and cancer.

with inflammatory disease. The repertoire of cancer patients autoantibodies in part overlaps that of autoimmune disease patients. Overall, the occurrence of autoantibodies is not followed by a better survival of cancer patients. However, the tumor-targeting autoantibodies induced in cancer patients deal with the immunosuppressive milieu in which they are developed and in which they would trigger their biological effects. On the other hand, autoimmune disorders often develop after alterations of tolerance checkpoints which induce Tregs dysfunctions and drive towards pro-inflammatory responses. Due to these different immunological microenvironments, autoantibodies with similar specificities may have different effects in cancer and autoimmune disease patients. Biological activities of autoantibodies to self antigens may induce paraneoplastic syndrome in cancer patients which might reflect the attempt of the patients to counteract the tumor growth. Recent studies have shown that patients with paraneoplastic syndrome have a spontaneous regression of tumors. The value of Tregs dysfunction in generating an immune response has been consolidated in patients with paraneoplastic syndromes while the increase of Tregs has been associated with poor prognosis in cancer patients. Accordingly, novel therapies have employed antibodies which target Tregs immune-checkpoint receptors. Encouraging results have been obtained following such therapy in cancer patients. The blockade of immune-checkpoint receptors by antibodies in cancer induces inflammatory adverse effects that mimic an autoimmune response in absence of immunosuppression.

Overall, the biological activities of autoantibodies in cancer might depend on their specificity, on their immunological properties and on the presence of a favorable microenvironment.

Autoantibodies found in cancer patients can be used as tool for the diagnosis of cancer.

The current knowledge on the spontaneous humoral responses occurring in cancer patients, on the mechanisms that trigger self antigens autoantibodies and on the mechanisms of their biological activities might help to furnish a rationale to design anti-cancer immunotherapeutic protocols.

## 10. ACKNOWLEDGMENT

This work was supported by a grant from the Department of Defence (Project aptamers). We thank Evelyn Carpenter for her help in English language editing. Rosanna Mattera is a recipient of the Sapienza PhD program in Molecular Medicine. We apologize to the colleagues whose articles have not been cited in this review because of space limitations.

## 11. REFERENCES

1. K. A. Mifflin, B. J. Kerr: Pain in autoimmune disorders. *J Neurosci Res* (2016)  
DOI: 10.1002/jnr.23844
2. R. I. Nurieva, X. Liu, C. Dong: Molecular mechanisms of T- cell tolerance. *Immunol Rev*, 241, 133-144 (2011)  
DOI: 10.1111/j.1600-065X.2011.01012.x
3. P. Zaenker, E. S. Gray, M. R. Ziman: Autoantibody production in cancer- The humoral immune response toward autologous antigens in cancer patients. *Autoimmun Rev*, 15, 477-483 (2016)  
DOI: 10.1016/j.autrev.2016.01.017

4. T. Fujii: Direct and indirect pathogenic roles of autoantibodies in systemic autoimmune diseases. *Allergol Int*, 63, 515-522 (2014)  
DOI: 10.2332/allergolint.14-RAI-0801
5. R. Bei, L. Masuelli, C. Palumbo, M. Modesti, A. Modesti: A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. *Cancer Lett*, 281, 8-23 (2009)  
DOI: 10.1016/j.canlet.2008.11.009
6. C. K. Heo, Y. Y. Bahk, E. W. Cho: Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. *BMB Rep*, 45, 677-685 (2012)  
DOI: 10.5483/BMBRep.2012.45.12.236
7. X. Zhang, A. Zambrano, Z. T. Lin, Y. Xing, J. Rippey, T. Wu: Immunosensors for biomarker detection in autoimmune diseases. *Arch Immunol Ther Exp (Warsz)* (2016)  
DOI: 10.1007/s00005-016-0419-5
8. A. Altintas, T. Cil, S. Pasa, R. Danis, I. Kilinc, O. Ayyildiz, E. Muftuoglu: Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non Hodgkin's lymphoma: a single center experience. *Minerva Med*, 99, 7-14 (2008)
9. S. Lv, J. Zhang, J. Wu, X. Zheng, Y. Chu, S. Xiong: Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. *Immunol Lett*, 99, 217-227 (2005)  
DOI: 10.1016/j.imlet.2005.03.019
10. K. N. Syrigos, A. Charalambopoulos, K. Pliarchopoulou, N. Varsamidakis, A. Machairas, D. Mandrekas: The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. *Anticancer Res*, 20, 4351-4353 (2000)
11. G. Yaniv, G. Twig, D. B. Shor, A. Furer, Y. Sherer, O. Mozes, O. Komisar, E. Slonimsky, E. Klang, E. Lotan, M. Welt, I. Marai, A. Shina, H. Amital, Y. Shoenfeld: A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. *Autoimmun Rev*, 14, 75-79 (2015)  
DOI: 10.1016/j.autrev.2014.10.003
12. S. Yamagiwa, H. Kamimura, M. Takamura, Y. Aoyagi: Autoantibodies in primary biliary cirrhosis: recent progress in research on the pathogenetic and clinical significance. *World J Gastroenterol*, 20, 2606-2612 (2014)  
DOI: 10.3748/wjg.v20.i10.2606
13. M. Maślińska, M. Przygodzka, B. Kwiatkowska, K. Sikorska-Siudek: Sjogren's syndrome: still not fully understood disease. *Rheumatol Int*, 35, 233-241 (2015)  
DOI: 10.1007/s00296-014-3072-5
14. S. Mehra, J. Walker, K. Patterson, M. J. Fritzler: Autoantibodies in systemic sclerosis. *Autoimmun Rev*, 12, 340-354 (2013)  
DOI: 10.1016/j.autrev.2012.05.011
15. F. Franceschini, I. Cavazzana: Anti-Ro/SSA and La/SSB antibodies. *Autoimmunity*, 38, 55-63 (2005)  
DOI: 10.1080/08916930400022954
16. C. Bencimon, G. Salles, A. Moreira, S. Guyomard, B. Coiffier, J. Bienvenu, N. Fabiena: Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin's lymphoma. *Ann N Y Acad Sci*, 1050, 319-326 (2005)  
DOI: 10.1196/annals.1313.034
17. Y. Hong, J. Long, H. Li, S. Chen, Q. Liu, B. Zhang, X. He, Y. Wang, H. Li, Y. Li, T. Zhang, C. Lu, H. Yan, M. Zhang, Q. Li, B. Cao, Z. Bai, J. Wang, Z. Zhang, S. Zhu, J. Zheng, X. Ou, H. Ma, J. Jia, H. You, S. Wang, J. Huang: An analysis of immunoreactive signatures in early stage hepatocellular carcinoma. *EBioMedicine*, 2, 438-446 (2015)  
DOI: 10.1016/j.ebiom.2015.03.010
18. K. Russo, S. Hoch, C. Dima, J. Varga, M. Teodorescu: Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. *J Rheumatol*, 27, 142-148 (2000)
19. D. P. Bogdanos, L. Komorowski: Disease-specific autoantibodies in primary biliary cirrhosis. *Clin Chim Acta*, 412, 502-512 (2011)  
DOI: 10.1016/j.cca.2010.12.019
20. A. Al-Shukaili, A. A. Al-Jabri, M. S. Al-Moundhri: Prognostic value of autoantibodies in the serum of Omani patients with gastric cancer. *Saudi Med J*, 27, 1873-1877 (2006)
21. C. A. von Mühlen, E. M. Tan: Autoantibodies in the diagnosis of systemic rheumatic

- diseases. *Semin Arthritis Rheum*, 24, 323-358 (1995)  
DOI: 10.1016/S0049-0172(95)80004-2
22. L. Breda, M. Nozzi, S. De Sanctis, F. Chiarelli: Laboratory tests in the diagnosis and follow-up of pediatric rheumatic disease: an update. *Semin Arthritis Rheum*, 40, 53-72 (2010)  
DOI: 10.1016/j.semarthrit.2008.12.001
  23. E. Piura, B. Piura: Autoantibodies to tailor-made panels of tumor-associated antigens in breast carcinoma. *J Oncol*, 2011, 982425 (2011)  
DOI: 10.1155/2011/982425
  24. H. Imai, K. Furuta, G. Landberg, K. Kiyosawa, L. F. Liu, E. M. Tan: Autoantibody to DNA topoisomerase II in primary liver cancer. *Clin Cancer Res*, 1, 417-424 (1995)
  25. I. Hayakawa, M. Hasegawa, K. Takehara, S. Sato: Anti-DNA topoisomerase II $\alpha$  autoantibodies in localized scleroderma. *Arthritis Rheum*, 50, 227-232 (2004)  
DOI: 10.1002/art.11432
  26. M. Liu, A. Varela-Ramirez, J. Li, L. Dai, R. J. Aguilera, J. Y. Zhang: Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma. *Oncol Rep*, 33, 2245-2252 (2015)  
DOI: 10.3892/or.2015.3854
  27. L. Dai, J. Li, M. Xing, T. W. Sanchez, C. A. Casiano, J. Y. Zhang: Using serological proteome analysis to identify serum anti-nucleophosmin1 autoantibody as a potential biomarker in European-American and African-American patients with prostate cancer. *Prostate*, 76, 1375-1386 (2016)  
DOI: 10.1002/pros.23217
  28. D. D. Taylor, C. Gercel-Taylor, L. P. Parker: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. *Gynecol Oncol*, 115, 112-120 (2009)  
DOI: 10.1016/j.ygyno.2009.06.031
  29. D. B. Ulanet, F. M. Wigley, A. C. Gelber, A. Rosen: Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. *Arthritis Rheum*, 49, 85-92 (2003)  
DOI: 10.1002/art.10914
  30. P. Moinzadeh, C. Fonseca, M. Hellmich, A. A. Shah, C. Chighizola, C. P. Denton, V. H. Ong: Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. *Arthritis Res Ther*, 16, R53 (2014)  
DOI: 10.1186/ar4486
  31. A. Suppiah, J. Greenman: Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. *World J Gastroenterol*, 19, 4651-4670 (2013)  
DOI: 10.3748/wjg.v19.i29.4651
  32. T. Himoto, H. Yoneyama, K. Kurokohchi, M. Inukai, H. Masugata, F. Goda, R. Haba, S. Watanabe, S. Senda, T. Masaki: Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases. *Can J Gastroenterol*, 26, 125-129 (2012)  
DOI: 10.1155/2012/890698
  33. P. Li, J. X. Shi, L. P. Dai, Y. R. Chai, H. F. Zhang, M. Kankonde, P. Kankonde, B. F. Yu, J. Y. Zhang: Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer. *Oncoimmunology*, 5, e1138200 (2016)  
DOI: 10.1080/2162402X.2016.1138200
  34. L. Dai, J. Li, R. Ortega, W. Qian, C. A. Casiano, J. Y. Zhang: Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. *J Immunol Res*, 2014, 827827 (2014)  
DOI: 10.1155/2014/827827
  35. S. Werner, H. Chen, S. Tao, H. Brenner: Systematic review: serum autoantibodies in the early detection of gastric cancer. *Int J Cancer*, 136, 2243-2252 (2015)  
DOI: 10.1002/ijc.28807
  36. J. Xia, J. Shi, P. Wang, C. Song, K. Wang, J. Zhang, H. Ye: Tumour-associated autoantibodies as diagnostic biomarkers for breast cancer: a systematic review and meta-analysis. *Scand J Immunol*, 83, 393-408 (2016)  
DOI: 10.1111/sji.12430
  37. T. Himoto, S. Kuriyama, J. Y. Zhang, E. K. Chan, Y. Kimura, T. Masaki, N. Uchida, M. Nishioka, E. M. Tan: Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. *Int J Oncol*, 27, 107985 (2005)  
DOI: 10.3892/ijo.27.4.1079



38. R. E. LaFond, R. B. Eaton, R. A. Watt, C. A. Vिलее, J. K. Actor, P. H. Schur: Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians. *Autoimmunity*, 13, 215-224 (1992)  
DOI: 10.3109/08916939209004827
39. K. Kashima, S. Yokoyama, T. Daa, K. Takahashi, I. Nakayama, S. Noguchi: c-myc expression is associated with increased proliferation activity in thyroid follicular cells of Graves' disease as stimulated by autoantibodies. *Eur J Endocrinol*, 135, 69-76 (1996)  
DOI: 10.1530/eje.0.1350069
40. M. Abu-Shakra, D. Buskila, M. Ehrenfeld, K. Conrad, Y. Shoenfeld: Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. *Ann Rheum Dis*, 60, 433-441 (2001)  
DOI: 10.1136/ard.60.5.433
41. J. Y. Zhang, C. A. Casiano, X. X. Peng, J. A. Koziol, E. K. Chan, E. M. Tan: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. *Cancer Epidemiol Biomarkers Prev*, 12, 136-143 (2003)
42. J. Y. Zhang, R. Megliorino, X. X. Peng, E. M. Tan, Y. Chen, E. K. Chan: Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. *J Hepatol*, 46, 107-114 (2007)  
DOI: 10.1016/j.jhep.2006.08.010
43. X. Liu, H. Ye, L. Li, W. Li, Y. Zhang, J. Y. Zhang: Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer. *J Immunol Res*, 2014, 326593 (2014)  
DOI: 10.1155/2014/326593
44. W. P. Maksymowych, G. Boire, D. van Schaardenburg, S. Wichuk, S. Turk, M. Boers, K. A. Siminovitch, V. Bykerk, E. Keystone, P. P. Tak, A. W. van Kuijk, R. Landewé, D. van der Heijde, M. Murphy, A. Marotta: 14-3-3 $\eta$  Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. *J Rheumatol*, 42, 1587-1594 (2015)  
DOI: 10.3899/jrheum.141385
45. X. Wang, J. Yu, A. Sreekumar, S. Varambally, R. Shen, D. Giacherio, R. Mehra, J. E. Montie, K. J. Pienta, M. G. Sanda, P. W. Kantoff, M. A. Rubin, J. T. Wei, D. Ghosh, A. M. Chinnaiyan: Autoantibody signatures in prostate cancer. *N Engl J Med*, 353, 1224-1235 (2005)  
DOI: 10.1056/NEJMoa051931
46. Y. Okazaki, A. Suzuki, T. Sawada, M. Ohtake-Yamanaka, T. Inoue, T. Hasebe, R. Yamada, K. Yamamoto: Identification of citrullinated eukaryotic translation initiation factor 4G1 as novel autoantigen in rheumatoid arthritis. *Biochem Biophys Res Commun*, 341, 94-100 (2006)  
DOI: 10.1016/j.bbrc.2005.12.160
47. O. H. Negm, M. R. Hamed, R. E. Schoen, R. L. Whelan, R. J. Steele, J. Scholefield, E. M. Dilnot, H. M. Shantha Kumara, J. F. Robertson, H. F. Sewell: Human blood autoantibodies in the detection of colorectal cancer. *PLoS One*, 11, e0156971 (2016)  
DOI: 10.1371/journal.pone.0156971
48. K. C. Cheng, H. Matsuoka, K. M. Lee, N. Kim, M. S. Krug, S. S. Kwon, M. Mora, T. J. Yoo: Proto-oncogene Raf1 as an autoantigen in Meniere's disease. *Ann Otol Rhinol Laryngol*, 109, 1093-1098 (2000)  
DOI: 10.1177/000348940010901201
49. G. Assmann, K. Shihadeh, V. Poeschel, N. Murawski, J. Conigliarou, M. F. Ong, M. Pfreundschuh: Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study. *PLoS One*, 9, e88177 (2014)  
DOI: 10.1371/journal.pone.0088177
50. R. Wu, O. Shovman, Y. Zhang, B. Gilburd, G. Zandman-Goddard, Y. Shoenfeld: Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. *Clin Rev Allergy Immunol*, 32, 47-56 (2007)  
DOI: 10.1007/BF02686081
51. F. Atzeni, P. Sarzi-Puttini, N. Lama, E. Bonacci, F. Bobbio-Pallavicini, C. Montecucco, R. Caporali: Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. *Arthritis Res Ther*, 10, R51 (2008)  
DOI: 10.1186/ar2420
52. H. Maejima, R. Aki, A. Watarai, K. Shirai, Y. Hamada, K. Katsuoka: Antibodies against cyclic citrullinated peptide in Japanese

- psoriatic arthritis patients. *J Dermatol*, 37, 339-345 (2010)  
DOI: 10.1111/j.1346-8138.2010.00814.x
53. N. P. Gupta, A. N. Malaviya, S. M. Singh: Rheumatoid factor: correlation with recurrence in transitional cell carcinoma of the bladder. *J Urol*, 121, 417-418 (1979)
  54. A. Schattner, A. Shani, M. Talpaz, Z. Bentwich: Rheumatoid factors in the sera of patient with gastrointestinal carcinoma. *Cancer*, 52, 2156-2161 (1983)  
DOI: 10.1002/1097-0142(19831201)52:11<2156::AID-CNCR2820521130>3.0.CO;2-2
  55. N. C. Kyriakidis, E. K. Kapsogeorgou, A. G. Tzioufas: A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms. *J Autoimmun*, 51, 67-74 (2014)  
DOI: 10.1016/j.jaut.2013.11.001
  56. M. Sánchez-Castañón, G. de las Heras-Castaño, M. López-Hoyos: Autoimmune pancreatitis: an underdiagnosed autoimmune disease with clinical, imaging and serological features. *Autoimmun Rev*, 9, 237-240 (2010)  
DOI: 10.1016/j.autrev.2009.07.003
  57. D. Aletaha, S. Blüml: Therapeutic implications of autoantibodies in rheumatoid arthritis. *RMD Open*, 2, e000009 (2016)  
DOI: 10.1136/rmdopen-2014-000009
  58. F. Fang, H. L. Wang, P. Ye, H. L. Deng, G. L. Dong, L. L. Ma, J. Wang: Detection of autoantibodies in the serum of primary hepatocarcinoma patients. *Hepatobiliary Pancreat Dis Int*, 1, 94-95 (2002)
  59. Y. Tomer, Y. Shoenfeld: Autoantibodies, autoimmunity and cancer. In: The decade of autoimmunity. Eds: Y Shoenfeld, ME Gershwin, Elsevier (2000)  
DOI: 10.1016/b978-044450331-2/50016-3
  60. S. Vernino, V. A. Lennon: Autoantibody profiles and neurological correlations of thymoma. *Clin Cancer Res*, 10, 7270-7275 (2004)  
DOI: 10.1158/1078-0432.CCR-04-0735
  61. M. V. Zeman, G. M. Hirschfield: Autoantibodies and liver disease: uses and abuses. *Can J Gastroenterol*, 24, 225-231 (2010)  
DOI: 10.1155/2010/431913
  62. S. Pedreira, E. Sugai, M. L. Moreno, H. Vázquez, S. Niveloni, E. Smecuol, R. Mazure, Z. Kogan, E. Mauriño, J. C. Bai: Significance of smooth muscle/anti actin autoantibodies in celiac disease. *Acta Gastroenterol Latinoam*, 35, 83-93 (2005)
  63. N. Prinzi, E. Baldini, S. Sorrenti, C. De Vito, C. Tuccilli, A. Catania, S. Carbotta, R. Mocini, C. Coccaro, A. Nesca, M. Bianchini, E. De Antoni, M. D'Armiento, S. Ulisse: Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients. *Breast Cancer Res Treat*, 144, 683-688 (2014)  
DOI: 10.1007/s10549-014-2893-y
  64. S. A. Rebuffat, M. Morin, B. Nguyen, F. Castex, B. Robert, S. Péraldi-Roux: Human recombinant anti-thyroperoxidase autoantibodies: *in vitro* cytotoxic activity on papillary thyroid cancer expressing TPO. *Br J Cancer*, 102, 852-861 (2010)  
DOI: 10.1038/sj.bjc.6605464
  65. W. M. Wiersinga: Thyroid autoimmunity. *Endocr Dev*, 26, 139-157 (2014)  
DOI: 10.1159/000363161
  66. A. Grzelka, A. Araszkievicz, A. Uruska, D. Zozulińska-Ziółkiewicz: Prevalence of anti-thyroid peroxidase in adults with type 1 diabetes participating in Poznań prospective study. *Adv Clin Exp Med*, 24, 79-84 (2015)  
DOI: 10.17219/acem/38149
  67. L. M. da Silva Kotze, R. M. Nisihara, S. R. da Rosa Utiyama, G. C. Piovezan, L. R. Kotze: Thyroid disorders in Brazilian patients with celiac disease. *J Clin Gastroenterol*, 40, 33-36 (2006)  
DOI: 10.1097/01.mcg.0000190756.63799.0f
  68. R. M. Innocencio, J. H. Romaldini, L. S. Ward: Thyroid autoantibodies in autoimmune diseases. *Medicina (B Aires)*, 64, 227-230 (2004)
  69. J. Qin, Z. Yu, H. Guan, L. Shi, Y. Liu, N. Zhao, Z. Shan, C. Han, Y. Li, W. Teng: High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma. *Dis Markers*, 2015, 648670 (2015)  
DOI: 10.1155/2015/648670
  70. C. Durante, S. Tognini, T. Montesano, F. Orlandi, M. Torlontano, E. Puxeddu, M. Attard, G. Costante, S. Tumino, D. Meringolo, R. Bruno, F. Trulli, M. Toteda, A. Redler,

- G. Ronga, S. Filetti, F. Monzani: Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. *Thyroid*, 24, 1139-1145 (2014)  
DOI: 10.1089/thy.2013.0698
71. F. A. Khan, N. Al-Jameil, M. F. Khan, M. Al-Rashid, H. Tabassum: Thyroid dysfunction: an autoimmune aspect. *Int J Clin Exp Med*, 8, 6677-6681 (2015)
  72. A. M. Al-Hakami: Pattern of thyroid, celiac, and anti-cyclic citrullinated peptide autoantibodies coexistence with type 1 diabetes mellitus in patients from Southwestern Saudi Arabia. *Saudi Med J*, 37, 386-391 (2016)  
DOI: 10.15537/smj.2016.4.13571
  73. A. Koszarny, M. Majdan, M. Dryglewska, J. Tabarkiewicz: Prevalence of selected organ-specific autoantibodies in rheumatoid arthritis and primary Sjögren's syndrome patients. *Reumatologia*, 53, 61-68 (2015)  
DOI: 10.5114/reum.2015.51504
  74. G. Ingrosso, M. Fantini, A. Nardi, M. Benvenuto, P. Sacchetti, L. Masuelli, E. Ponti, G. V. Frajese, F. Lista, O. Schillaci, R. Santoni, A. Modesti, R. Bei: Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients. *Oncol Rep* 29, 1167-1174 (2013)  
DOI: 10.3892/or.2012.2197
  75. A. Vojdani: Antibodies as predictors of complex autoimmune diseases. *Int J Immunopathol Pharmacol*, 21, 267-278 (2008)  
DOI: 10.1517/17530059.2.6.593
  76. M. H. Foster: Basement membranes and autoimmune diseases. *Matrix Biol*, pii: S0945-053X(16)30147-0 (2016)  
DOI: 10.1016/j.matbio.2016.07.008
  77. D. T. Woodley, C. Chang, P. Saadat, R. Ram, Z. Liu, M. Chen: Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. *J Invest Dermatol* 124, 958-964 (2005)  
DOI: 10.1111/j.0022-202X.2005.23702.x
  78. R. Bei, L. Masuelli, C. Palumbo, I. Tresoldi, A. Scardino, A. Modesti: Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules. *Int Rev Immunol*, 27, 137-175 (2008)  
DOI: 10.1080/08830180801939280
  79. S. Kobold, T. Lütken, Y. Cao, C. Bokemeyer, D. Atanackovic: Autoantibodies against tumor-related antigens: Incidence and biologic significance. *Hum Immunol*, 71, 643-651 (2010)  
DOI: 10.1016/j.humimm.2010.03.015
  80. A. L. Young, E. E. Bailey, S. M. Colaço, D. E. Engler, M. E. Grossman: Anti-laminin332 mucous membrane pemphigoid associated with recurrent metastatic prostate carcinoma: hypothesis for a paraneoplastic phenomenon. *Eur J Dermatol*, 21, 401-404 (2011)  
DOI: 10.1684/ejd.2011.1360
  81. P. Bodzek, R. Partyka, A. Damasiewicz-Bodzek: Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer. *J Ovarian Res*, 7, 30 (2014)  
DOI: 10.1186/1757-2215-7-30
  82. J. E. Alard, M. Dueymes, P. Youinou, C. Jamin: Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. *Autoimmun Rev*, 6, 438-443 (2007)  
DOI: 10.1016/j.autrev.2007.01.012
  83. G. Adamus, R. Bonnah, L. Brown, L. David: Detection of autoantibodies against heat shock proteins and collapsin response mediator proteins in autoimmune retinopathy. *BMC Ophthalmol*, 13, 48 (2013)  
DOI: 10.1186/1471-2415-13-48
  84. M. Kasperkiewicz, S. Tukaj, A. J. Gembicki, P. Silló, A. Görög, D. Zillikens, S. Kárpáti: Evidence for a role of autoantibodies to heat shock protein 60, 70, and 90 in patients with dermatitis herpetiformis. *Cell Stress Chaperones*, 19, 837-843 (2014)  
DOI: 10.1007/s12192-014-0507-6
  85. C. T. Wu, L. S. Ou, K. W. Yeh, W. I. Lee, J. L. Huang: Serum heat shock protein 60 can predict remission of flareup in juvenile idiopathic arthritis. *Clin Rheumatol*, 30, 959-965 (2011)  
DOI: 10.1007/s10067-011-1709-2

86. F. Tahiri, F. Le Naour, S. Huguet, R. Lai-Kuen, D. Samuel, C. Johanet, B. Saubamea, V. Tricottet, J. C. Duclos-Vallee, E. Ballot: Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. *Hepatology*, 47, 937-948 (2008)  
DOI: 10.1002/hep.22149
87. M. Takashima, Y. Kuramitsu, Y. Yokoyama, N. Iizuka, T. Harada, M. Fujimoto, I. Sakaida, K. Okita, M. Oka, K. Nakamura: Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. *Proteomics*, 6, 3894-3900 (2006)  
DOI: 10.1002/pmic.200500346
88. Y. Q. Tong, Z. J. Zhang, B. Liu, J. Huang, H. Liu, Y. Liu, F. J. Guo, G. H. Zhou, P. L. Xie, Y. H. Li, C. H. Zuo, J. Y. Hu, G. C. Li: Autoantibodies as potential biomarkers for nasopharyngeal carcinoma. *Proteomics*, 8, 3185-3193 (2008)  
DOI: 10.1002/pmic.200700651
89. N. Tovar, C. Fernández de Larrea, F. Pedrosa, J. I. Aróstegui, M. T. Cibeira, L. Rosiñol, M. Elena, X. Filella, J. Yagüe, J. Bladé: Differential humoral responses against heatshock proteins after autologous stem cell transplantation in multiple myeloma. *Ann Hematol*, 93, 107-111 (2014)  
DOI: 10.1007/s00277-013-1942-7
90. S. Boonjaraspinyo, A. Juasook, T. Boonmars, R. Aukkanimart, A. Silsirivanit, W. Loilome, P. Sriraj, Z. Wu, P. Ratanasawan: A promising serum autoantibody marker, anti-heat shock protein 90 $\alpha$ , for cholangiocarcinoma. *Asian Pac J Cancer Prev*, 16, 5779-5785 (2015)  
DOI: 10.7314/APJCP.2015.16.14.5779
91. S. Tukaj, D. Zillikens, M. Kasperkiewicz: Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases. *Exp Dermatol*, 24, 567-571 (2015)  
DOI: 10.1111/exd.12760
92. Q. Shao, P. Ren, Y. Li, B. Peng, L. Dai, N. Lei, W. Yao, G. Zhao, L. Li, J. Zhang: Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. *Int J Oncol*, 41, 1061-1067 (2012)  
DOI: 10.3892/ijo.2012.1515
93. A. Raiter, A. Vilkin, R. Gingold, Z. Levi, M. Halpern, Y. Niv, B. Hardy: The presence of anti-GRP78 antibodies in the serum of patients with colorectal carcinoma: a potential biomarker for early cancer detection. *Int J Biol Markers*, 29, e4315 (2014)  
DOI: 10.5301/ijbm.5000086
94. M. Gonzalez-Gronow, M. Cuchacovich, C. Llanos, C. Urzua, G. Gawdi, S. V. Pizzo: Prostate cancer cell proliferation *in vitro* is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. *Cancer Res*, 66, 11424-11431 (2006)  
DOI: 10.1158/0008-5472.CAN-06-1721
95. H. C. Yu, P. H. Lai, N. S. Lai, H. B. Huang, M. Koo, M. C. Lu: Increased Serum Levels of Anti-Carbamylated 78-kDa Glucose-Regulated Protein Antibody in Patients with Rheumatoid Arthritis. *Int J Mol Sci*, 17, pii: E1510 (2016)  
DOI: 10.3390/ijms17091510
96. T. Matsumoto, S. Ryuge, M. Kobayashi, T. Kageyama, M. Hattori, N. Goshima, S. X. Jiang, M. Saegusa, A. Iyoda, Y. Satoh, N. Masuda, Y. Sato: Anti-HuC and -HuD autoantibodies are differential sero-diagnostic markers for small cell carcinoma from large cell neuroendocrine carcinoma of the lung. *Int J Oncol*, 40, 1957-1962 (2012)  
DOI: 10.3892/ijo.2012.1405
97. J. Honnorat, A. Didelot, E. Karantoni, D. Ville, F. Ducray, L. Lambert, K. Deiva, M. Garcia, P. Pichit, G. Cavillon, V. Rogemond, J. Y. DeLattre, M. Tardieu: Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. *Neurology*, 80, 2226-2232 (2013)  
DOI: 10.1212/WNL.0b013e318296e9c3
98. J. W. de Beukelaar, P. A. Sillevius Smitt: Managing paraneoplastic neurological disorders. *Oncologist*, 11, 292-305 (2006)  
DOI: 10.1634/theoncologist.11-3-292
99. K. C. Hsiao, N. Y. Shih, P. Y. Chu, Y. M. Hung, J. Y. Liao, S. W. Chou, Y. Y. Yang, G. C. Chang, K. J. Liu: Anti- $\alpha$ -enolase is a prognostic marker in postoperative lung cancer patients. *Oncotarget*, 6, 35073-35086 (2015)  
DOI: 10.18632/oncotarget.5316
100. M. Capello, C. Caorsi, P. J. Bogantes Hernandez, E. Dametto, F. E. Bertinetto, P. Magistroni, S. Rendine, A. Amoroso, F. Novelli: Phosphorylated alpha-enolase

- induces autoantibodies in HLA-DR8 pancreatic cancer patients and triggers HLA-DR8 restricted T-cell activation. *Immunol Lett*, 167, 11-16 (2015)  
DOI: 10.1016/j.imlet.2015.06.008
101. Z. Mojtahedi, A. Safaei, Z. Yousefi, A. Ghaderi: Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. *OMICS*, 15, 409-418 (2011)  
DOI: 10.1089/omi.2010.0131
102. C. López-Pedrera, J. M. Villalba, E. Siendones, N. Barbarroja, C. Gómez-Díaz, A. Rodríguez-Ariza, P. Buendía, A. Torres, F. Velasco: Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. *Proteomics*, 6, S293-S299 (2006)  
DOI: 10.1002/pmic.200500384
103. S. Shukla, A. Pranay, A. K. D'Cruz, P. Chaturvedi, S. V. Kane, S. M. Zingde: Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response. *Cancer Biomark*, 5, 127-135 (2009)  
DOI: 10.3233/CBM-2009-0604
104. P. L. Triozzi, W. Aldrich, J. W. Crabb, A. D. Singh: Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma. *Melanoma Res*, 25, 510-518 (2015)  
DOI: 10.1097/CMR.0000000000000207
105. B. Terrier, N. Degand, P. Guilpain, A. Servettaz, L. Guillevin, L. Mouthon: Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. *Autoimmun Rev*, 6, 176-182 (2007)  
DOI: 10.1016/j.autrev.2006.10.004
106. M. Lopez-Sublet, H. Bihan, G. Reach, S. Dupont, A. Didelot, J. J. Mourad, A. Krivitzky, R. Dhote: Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy. *Diabetes Metab*, 38, 273-275 (2012)  
DOI: 10.1016/j.diabet.2012.02.005
107. F. Ali, M. Rowley, B. Jayakrishnan, S. Teuber, M. E. Gershwin, I. R. Mackay: Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. *J Autoimmun*, 37, 79-87 (2011)  
DOI: 10.1016/j.jaut.2011.05.005
108. D. A. Pearce, M. Atkinson, D. A. Tagle: Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. *Neurology*, 63, 2001-2005 (2004)  
DOI: 10.1212/01.WNL.0000145836.72059.3B
109. M. Dordić, I. Z. Matić, I. Filipović-Lješković, R. Džodić, M. Sašić, A. Erić-Nikolić, A. Vuletić, B. Kolundžija, A. Damjanović, N. Grozdanić, S. Nikolić, J. Pralica, D. Dobrosavljević, S. Rašković, S. Andrejević, Z. Juranić: Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo. *BMC Complement Altern Med*, 12, 109 (2012)  
DOI: 10.1186/1472-6882-12-109
110. N. Landegren, D. Sharon, A. K. Shum, I. S. Khan, K. J. Fasano, Å. Hallgren, C. Kampf, E. Freyhult, B. Ardesjö-Lundgren, M. Alimohammadi, S. Rathsmann, J. F. Ludvigsson, D. Lundh, R. Motrich, V. Rivero, L. Fong, A. Giwerzman, J. Gustafsson, J. Perheentupa, E. S. Husebye, M. S. Anderson, M. Snyder, O. Kämpe: Transglutaminase 4 as a prostate autoantigen in male subfertility. *Sci Transl Med*, 7, 292ra101 (2015)  
DOI: 10.1126/scitranslmed.aaa9186
111. S. Hu, A. Vissink, M. Arellano, C. Roozendaal, H. Zhou, C. G. Kallenberg, D. T. Wong: Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays. *Proteomics*, 11, 1499-1507 (2011)  
DOI: 10.1002/pmic.201000206
112. M. Sánchez-Castañón, G. de Las Heras-Castaño, C. Gómez, M. López-Hoyos: Differentiation of autoimmune pancreatitis from pancreas cancer: utility of anti-amylase and anti-carbonic anhydrase II autoantibodies. *Auto Immun Highlights*, 3, 11-17 (2011)  
DOI: 10.1007/s13317-011-0024-x
113. K. Yoshiura, T. Nakaoka, T. Nishishita, K. Sato, A. Yamamoto, S. Shimada, T. Saida, Y. Kawakami, T. A. Takahashi, H. Fukuda, S. Imajoh-Ohmi, N. Oyaizu, N. Yamashita: Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy. *Clin Cancer Res*, 11, 8201-8207 (2005)  
DOI: 10.1158/1078-0432.CCR-05-0816

114. Y. Itoh, M. Reichlin: Antibodies to carbonic anhydrase in systemic lupus erythematosus and other rheumatic diseases. *Arthritis Rheum*, 35, 73-82 (1992)  
DOI: 10.1002/art.1780350112
115. G. Adamus, S. Yang, R. G. Weleber: Unique epitopes for carbonic anhydrase II autoantibodies related to autoimmune retinopathy and cancer-associated retinopathy. *Exp Eye Res*, 147, 161-168 (2016)  
DOI: 10.1016/j.exer.2016.05.012
116. T. Taniguchi, K. Okazaki, M. Okamoto, S. Seko, J. Tanaka, K. Uchida, K. Nagashima, T. Kurose, Y. Yamada, T. Chiba, Y. Seino: High prevalence of autoantibodies against carbonic anhydrase II and lactoferrin in type 1 diabetes: concept of autoimmune exocrinopathy and endocrinopathy of the pancreas. *Pancreas*, 27, 26-30 (2003)  
DOI: 10.1097/00006676-200307000-00004
117. P. Invernizzi, P. M. Battezzati, A. Crosignani, P. Zermiani, M. Bignotto, N. Del Papa, M. Zuin, M. Podda: Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. *Clin Exp Immunol*, 114, 448-454 (1998)  
DOI: 10.1046/j.1365-2249.1998.00735.x
118. A. Alver, A. Menteşe, S. C. Karahan, C. Erem, E. E. Keha, M. K. Arikan, M. S. Eminağaoğlu, O. Deger: Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease. *Exp Clin Endocrinol Diabetes*, 115, 287-291 (2007)  
DOI: 10.1055/s-2007-960498
119. C. Alessandri, M. Bombardieri, R. Scrivo, F. Viganego, F. Conti, N. de Luca, V. Ricciari, G. Valesini: Anti-carbonic anhydrase II antibodies in systemic sclerosis: association with lung involvement. *Autoimmunity*, 36, 85-89 (2003)  
DOI: 10.1080/0891693031000079239
120. G. A. Lang, G. R. Yeaman: Autoantibodies in endometriosis sera recognize a Thomsen-Friedenreich-like carbohydrate antigen. *J Autoimmun*, 16, 151-161 (2001)  
DOI: 10.1006/jaut.2000.0465
121. Y. Takasaki, K. Kaneda, M. Matsushita, H. Yamada, M. Nawata, R. Matsudaira, M. Asano, R. Mineki, N. Shindo, H. Hashimoto: Glyceraldehyde 3-phosphate dehydrogenase is a novel autoantigen leading autoimmune responses to proliferating cell nuclear antigen multiprotein complexes in lupus patients. *Int Immunol*, 16, 1295-1304 (2004)  
DOI: 10.1093/intimm/dxh131
122. R. Ummanni, D. Duscharla, C. Barrett, S. Venz, T. Schlomm, H. Heinzer, R. Walther, C. Bokemeyer, T. H. Brümmendorf, P. V. Murthy, S. Balabanov: Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers. *J Proteomics*, 119, 218-229 (2015)  
DOI: 10.1016/j.jprot.2015.02.005
123. Y. Fujita, T. Nakanishi, M. Hiramatsu, H. Mabuchi, Y. Miyamoto, A. Miyamoto, A. Shimizu, N. Tanigawa: Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. *Clin Cancer Res*, 12, 6415-6420 (2006)  
DOI: 10.1158/1078-0432.CCR-06-1315
124. J. Solassol, T. Maudelonde, A. Mange, J. L. Pujol: Clinical relevance of autoantibody detection in lung cancer. *J Thorac Oncol*, 6, 955-962 (2011)  
DOI: 10.1097/JTO.0b013e318215a0a4
125. R. Karasawa, S. Ozaki, K. Nishioka, T. Kato: Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. *Microbiol Immunol*, 49, 57-65 (2005)  
DOI: 10.1111/j.1348-0421.2005.tb03640.x
126. R. Karasawa, M. S. Kurokawa, K. Yudoh, K. Masuko, S. Ozaki, T. Kato: Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis. *Clin Exp Immunol*, 161, 459-470 (2010)  
DOI: 10.1111/j.1365-2249.2010.04218.x
127. F. Yang, Z. Q. Xiao, X. Z. Zhang, C. Li, P. F. Zhang, M. Y. Li, Y. Chen, G. Q. Zhu, Y. Sun, Y. F. Liu, Z. C. Chen: Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. *J Proteome Res*, 6, 751-758 (2007)  
DOI: 10.1021/pr0602287
128. R. B. Mansour, S. Lassoued, B. Gargouri, A. El Gaïd, H. Attia, F. Fakhfakh: Increased levels of autoantibodies against catalase and superoxide dismutase associated with oxidative stress in patients with rheumatoid



- arthritis and systemic lupus erythematosus. *Scand J Rheumatol*, 37, 103-108 (2008)  
DOI: 10.1080/03009740701772465
129. T. Osaki, D. Sugiyama, Y. Magari, M. Souri, A. Ichinose: Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90 % of cases with autoimmune haemorrhaphilia XIII/13. *Thromb Haemost*, 113, 1347-1356 (2015)  
DOI: 10.1160/TH14-09-0745
130. P. R. Ames, L. Iannaccone, J. D. Alves, A. Margarita, L. R. Lopez, V. Brancaccio: Factor XIII in primary antiphospholipid syndrome. *J Rheumatol*, 32, 1058-1062 (2005)
131. E. B. Roth, P. Stenberg, C. Book, K. Sjöberg: Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis--new pathways to epitope spreading. *Clin Exp Rheumatol*, 24, 12-18 (2006)
132. R. Bei, L. Masuelli, P. Trono, P. L. Orvietani, S. Losito, L. Marzocchella, D. Vitolo, L. Albonici, M. A. Mrozek, E. Di Gennaro, F. Lista, G. Faggioni, F. Ionna, L. Binaglia, V. Manzari, A. Budillon, A. Modesti. The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas. *Int J Oncol*, 31, 1301-1308 (2007)  
DOI: 10.3892/ijo.31.6.1301
133. L. Marzocchella, V. Sini, O. Buonomo, A. Orlandi, L. Masuelli, E. Bonanno, F. Lista, M. Turriziani, V. Manzari, M. Roselli, A. Modesti, R. Bei. Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice. *Cancer Sci*, 102, 509-515 (2011)  
DOI: 10.1111/j.1349-7006.2010.01814.x
134. M. Benvenuto, P. Sileri, P. Rossi, L. Masuelli, M. Fantini, M. Nanni, L. Franceschilli, G. Sconocchia, G. Lanzilli, R. Arriga, G. Faggioni, F. Lista, A. Orlandi, V. Manzari, A. L. Gaspari, A. Modesti, R. Bei: Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients. *J Transl Med*, 13, 101 (2015)  
DOI: 10.1186/s12967-015-0455-7
135. A. L. Calich, V. S Viana, E. Cancado, F. Tustum, D. R. Terrabuio, E. P. Leon, C. A. Silva, E. F. Borba, E. Bonfa: Antiribosomal P protein: a novel antibody in autoimmune hepatitis. *Liver Int*, 33, 909-913 (2013)  
DOI: 10.1111/liv.12155
136. T. Naniwa, Y. Sugiura, S. Banno, T. Yoshinouchi, Y. Matsumoto, R. Ueda: Ribosomal P protein P0 as a candidate for the target antigen of anti-endothelial cell antibodies in mixed connective tissue disease. *Clin Exp Rheumatol*, 25, 593-598 (2007)
137. F. Fernández-Madrid, M. C. Maroun, O. A. Olivero, M. Long, A. Stark, L. I. Grossman, W. Binder, J. Dong, M. Burke, S. D. Nathanson, R. Zarbo, D. Chitale, R. Z. Chávez, C. Peebles: Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. *BMC Cancer*, 15, 407 (2015)  
DOI: 10.1186/s12885-015-1385-8
138. M. Tomizawa, F. Shinozaki, K. Fugo, Y. Motoyoshi, T. Sugiyama, S. Yamamoto, T. Kishimoto, N. Ishige: Anti-mitochondrial M2 antibody-positive autoimmune hepatitis. *Exp Ther Med*, 10, 1419-1422 (2015)  
DOI: 10.3892/etm.2015.2694
139. M. C. Maroun, O. Olivero, L. Lipovich, A. Stark, L. Tait S. Bandyopadhyay, M. Burke, R. Zarbo, D. Chitale, S. D. Nathanson, M. Long, C. Peebles, F. Fernández-Madrid: Anti-centrosome antibodies in breast cancer are the expression of autoimmunity. *Immunol Res*, 60, 339-347 (2014)  
DOI: 10.1007/s12026-014-8582-4
140. B. M. Reipert, S. Tanneberger, A. Pannetta, M. Bedosti, M. Poell, K. Zimmermann, M. T. Stellamor: Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? *Cancer Immunol Immunother*, 54, 1038-1042 (2005)  
DOI: 10.1007/s00262-005-0679-0
141. A. Takata-Tomokuni, A. Ueki, M. Shiwa, Y. Isozaki, T. Hatayama, H. Katsuyama, F. Hyodoh, W. Fujimoto, H. Ueki, M. Kusaka, H. Arikuni, T. Otsuki: Detection, epitope-mapping and function of anti-Fas autoantibody in patients with silicosis. *Immunology*, 116, 21-29 (2005)  
DOI: 10.1111/j.1365-2567.2005.02192.x
142. A. Maselli, S. Capoccia, P. Pugliese, C. Raggi, F. Cirulli, A. Fabi, W. Malorni, M.

- Pierdominici, E. Ortona: Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation. *Oncoimmunology*, 5, e1074375 (2015)  
DOI: 10.1080/2162402X.2015.1074375
143. E. Ortona, M. Pierdominici, L. Berstein: Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. *J Steroid Biochem Mol Biol*, 144 Pt B, 260-267 (2014)  
DOI: 10.1016/j.jsbmb.2014.07.004
144. P. Cufi, P. Soussan, F. Truffault, R. Fetouchi, M. Robinet, E. Fadel, S. Berrih-Aknin, R. Le Panse: Thymoma-associated myasthenia gravis: On the search for a pathogen signature. *J Autoimmun*, 52, 29-35 (2014)  
DOI: 10.1016/j.jaut.2013.12.018
145. D. Q. Zhang, R. Wang, T. Li, X. Li, Y. Qi, J. Wang, L. Yang: Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis. *J Neuroimmunol*, 283, 7-10 (2015)  
DOI: 10.1016/j.jneuroim.2015.04.004
146. E. H. Denys, V. A. Lennon: Asymptomatic Lambert-Eaton syndrome. *Muscle Nerve*, 49, 764-767 (2014)  
DOI: 10.1002/mus.24126
147. A. Thanou-Stavraki, J. A. James: Primary Sjogren's syndrome: current and prospective therapies. *Semin Arthritis Rheum*, 37, 273-292 (2008)  
DOI: 10.1016/j.semarthrit.2007.06.002
148. Y. M. Pers, C. Jorgensen: Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. *Immunotherapy*, 8, 109-116 (2016)  
DOI: 10.2217/imt-2016-0003
149. F. Cañas, L. Simonin, F. Couturaud, Y. Renaudineau: Annexin A2 autoantibodies in thrombosis and autoimmune diseases *Thromb Res*, 135, 226-230 (2015)  
DOI: 10.1016/j.thromres.2014.11.034
150. Y. Huang, C. Zhang, C. Chen, S. Sun, H. Zheng, S. Wan, Q. Meng, Y. Chen, J. Wei: Investigation of circulating antibodies to ANXA1 in breast cancer. *Tumour Biol*, 36, 123-136 (2015)  
DOI: 10.1007/s13277-014-2751-x
151. J. Song, X. Sun, L. J. Sokoll, M. Maki, Y. Tian, D. W. Chan, Z. Zhang: Detection of autoantibodies to annexin A11 in different types of human cancer. *Clin Proteom*, 5, 125-131 (2009)  
DOI: 10.1007/s12014-009-9031-6
152. L. Iaccarino, A. Ghirardello, M. Canova, M. Zen, S. Bettio, L. Nalotto, L. Punzi, A. Doria: Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. *Autoimmun Rev*, 10, 553-558 (2011)  
DOI: 10.1016/j.autrev.2011.04.007
153. M. Petri, A. C. Ho, J. Patel, D. Demers, J. M. Joseph, D. Goldman: Elevation of maternal alpha-fetoprotein in systemic lupus erythematosus: a controlled study. *J Rheumatol*, 22, 1365-1368 (1995)
154. Y. Y. Wu, A. V. Nguyen, X. X. Wu, M. Loh, M. Vu, Y. Zou, Q. Liu, P. Guo, Y. Wang, L. L. Montgomery, A. Orlofsky, J. H. Rand, E. Y. Lin: Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression. *Am J Pathol*, 184, 3359-3375 (2014)  
DOI: 10.1016/j.ajpath.2014.07.027
155. S. Battistelli, M. Stefanoni, R. Petrioli, A. Genovese, R. Dell'avanzato, G. Donati, A. Vittoria, F. Roviello: Antiphospholipid antibodies and acute-phase response in non-metastatic colorectal cancer patients. *Int J Biol Markers*, 23, 31-35 (2008)
156. K. J. Kim, I. W. Baek, K. S. Park, W. U. Kim, C. S. Cho: Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. *Lupus*, 2016, pii: 0961203316658557 (2016).  
DOI: 10.1177/0961203316658557
157. M. Khamashta, M. Taraborelli, S. Sciascia, A. Tincani: Antiphospholipid syndrome. *Best Pract Res Clin Rheumatol*, 30, 133-148 (2016)  
DOI: 10.1177/0961203316658557
158. R. Rai, T. Swetha: Association of antiphospholipid antibodies with connective tissue diseases. *Indian Dermatol Online J*, 6, 89-91 (2015)  
DOI: 10.4103/2229-5178.153009
159. M. Zivkovic, M. Zlatanovic, G. Zlatanovic, J. Djordjevic-Jocic, S. Cekic S: Anticardiolipin antibodies in patients with Behcet's disease. *Bosn J Basic Med Sci*, 11, 58-61 (2011)

160. D. Mimouni, G. J. Anhalt, Z. Lazarova, S. Aho, S. Kazerounian, D. J. Kouba, J. M. Jr Mascaró, H. C. Nousari: Paraneoplastic pemphigus in children and adolescents. *Br J Dermatol*, 147, 725-732 (2002)  
DOI: 10.1046/j.1365-2133.2002.04992.x
161. H. Koga, D. Tsuruta, B. Ohyama, N. Ishii, T. Hamada, C. Ohata, M. Furumura, T. Hashimoto: Desmoglein 3, its pathogenicity and a possibility for therapeutic target in pemphigus vulgaris. *Expert Opin Ther Targets*, 17, 293-306 (2013)  
DOI: 10.1517/14728222.2013.744823
162. M. Ahlemann, B. Schmitt, P. Stieber, O. Gires, S. Lang, R. Zeidler: Evaluation of CK8-specific autoantibodies in carcinomas of distinct localisations. *Anticancer Res*, 26, 783-789 (2006)
163. F. Le Naour, F. Brichory, D. E. Misek, C. Bréchet, S. M. Hanash, L. Beretta: A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. *Mol Cell Proteomics*, 1, 197-203 (2002)  
DOI: 10.1074/mcp.M100029-MCP200
164. X. Wang, P. Chen, J. Cui, C. Yang, H. Du: Keratin 8 is a novel autoantigen of rheumatoid arthritis. *Biochem Biophys Res Commun*, 465, 665-669 (2015)  
DOI: 10.1016/j.bbrc.2015.07.161
165. M. Murota, M. Nishioka, J. Fujita, N. Dobashi, F. Wu, Y. Ohtsuki, S. Hojo, J. Takahara, S. Kuriyama: Anti-cytokeratin antibodies in sera of the patients with autoimmune hepatitis. *Clin Exp Immunol*, 125, 291-299 (2001)  
DOI: 10.1046/j.1365-2249.2001.01568.x
166. P. Zaenker, M. R. Ziman: Serologic autoantibodies as diagnostic cancer biomarkers--a review. *Cancer Epidemiol Biomarkers Prev*, 22, 2161-2181 (2013)  
DOI: 10.1158/1055-9965.EPI-13-0621
167. X. Liu, H. Ye, L. Li, W. Li, Y. Zhang, J. X. Zhang: Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer. *J Immunol Res*, 2014, 326593 (2014)  
DOI: 10.1155/2014/326593
168. J. K. Yi, J. W. Chang, W. Han, J. W. Lee, E. Ko, D. H. Kim, J. Y. Bae, J. Yu, C. Lee, M. H. Yu, D. Y. Noh: Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. *Cancer Epidemiol Biomarkers Prev*, 18, 1357-1364 (2009)  
DOI: 10.1158/1055-9965.EPI-08-0696
169. G. Effraimidis, W. M. Wiersinga: Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. *Eur J Endocrinol*, 170, R241-252 (2014)  
DOI: 10.1530/EJE-14-0047
170. P. H. Plotz: The autoantibody repertoire: searching for order. *Nat Rev Immunol*, 3, 73-78 (2003)  
DOI: 10.1038/nri976
171. P. Matzinger: The danger model: a renewed sense of self. *Science*, 296, 301-305 (2002)  
DOI: 10.1126/science.1071059
172. L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, G. Kroemer: Immunogenic cell death in cancer and infectious disease. *Nat Rev Immunol* (2016)  
DOI: 10.1038/nri.2016.107
173. C. Backes, N. Ludwig, P. Leidinger, C. Harz, J. Hoffmann, A. Keller, E. Meese, H. P. Lenhof: Immunogenicity of autoantigens. *BMC Genomics*, 12, 340 (2011)  
DOI: 10.1186/1471-2164-12-340
174. M. M. Gubin, M. N. Artyomov, E. R. Mardis, R. D. Schreiber: Tumor neoantigens: building a framework for personalized cancer immunotherapy. *J Clin Invest*, 125, 3413-3421 (2015)  
DOI: 10.1172/JCI80008
175. R. Bareli, C. J. Cohen: MHC-multimer guided isolation of neoepitopes specific T cells as a potent-personalized cancer treatment strategy. *Oncoimmunology*, 5, e1159370 (2016)  
DOI: 10.1080/2162402X.2016.1159370
176. J. J. Oppenheim, H. F. Dong, P. Plotz, R. R. Caspi, M. Dykstra, S. Pierce, R. Martin, C. Carlos, O. Finn, O. Koul, O. M. Howard: Autoantigens act as tissue-specific chemoattractants. *J Leukoc Biol*, 77, 854-861 (2005)  
DOI: 10.1189/jlb.1004623
177. C. Kowal, L. A. DeGiorgio, T. Nakaoka, H. Hetherington, P. T. Huerta, B. Diamond, B. T. Volpe: Cognition and immunity: antibody impairs memory. *Immunity*, 21, 179-188 (2004)  
DOI: 10.1016/j.immuni.2004.07.011

178. M. Magna, D. S. Pisetsky: The role of cell death in the pathogenesis of SLE: is pyroptosis the missing link? *Scand J Immunol*, 82, 218-224 (2015)  
DOI: 10.1111/sji.12335
179. G. Robitaille, M. S. Christin, I. Clément, J. L. Senécal, Y. Raymond: Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. *Arthritis Rheum*, 60, 2805-2816 (2009)  
DOI: 10.1002/art.24765
180. M. B. de Siqueira, L. M. da Mota, S. C. Couto, M. I. Muniz-Junqueira: Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides. *BMC Musculoskeletal Disorders*, 16, 159 (2015)  
DOI: 10.1186/s12891-015-0616-0
181. M. C. Lu, N. S. Lai, H. C. Yu, H. B. Huang, S. C. Hsieh, C. L. Yu: Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. *Arthritis Rheum*, 62, 1213-1223 (2010)  
DOI: 10.1002/art.27386
182. M. C. Lu, C. L. Yu, H. C. Yu, H. B. Huang, M. Koo, N. S. Lai: Anti-citrullinated protein antibodies promote apoptosis of mature human Saos-2 osteoblasts via cell-surface binding to citrullinated heat shock protein 60. *Immunobiology*, 221, 76-83 (2016)  
DOI: 10.1016/j.imbio.2015.07.019
183. R. J. Falk, R. S. Terrell, L. A. Charles, J. C. Jennette: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals *in vitro*. *Proc Natl Acad Sci U S A*, 87, 4115-4119 (1990)  
DOI: 10.1073/pnas.87.11.4115
184. S. A. Rebuffat, B. Nguyen, B. Robert, F. Castex, S. Peraldi-Roux: Antithyroperoxidase antibody-dependent cytotoxicity in autoimmune thyroid disease. *J Clin Endocrinol Metab*, 93, 929-934 (2008)  
DOI: 10.1210/jc.2007-2042
185. Y. Tomer: Anti-thyroglobulin autoantibodies in autoimmune thyroid diseases: cross-reactive or pathogenic? *Clin Immunol Immunopathol*, 82, 3-11 (1997)  
DOI: 10.1006/clin.1996.4243
186. U. K. Misra, S. V. Pizzo: Modulation of the unfolded protein response in prostate cancer cells by antibody-directed against the carboxyl-terminal domain of GRP78. *Apoptosis*, 15, 173-182 (2010)  
DOI: 10.1007/s10495-009-0430-y
187. G. G. de Ridder, R. Ray, S. V. Pizzo: A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice. *Melanoma Res*, 22, 225-235 (2012)  
DOI: 10.1097/CMR.0b013e32835312fd
188. M. Cohen, P. Petignat: Purified autoantibodies against glucose-regulated protein 78 (GRP78) promote apoptosis and decrease invasiveness of ovarian cancer cells. *Cancer Lett*, 309, 104-109 (2011)  
DOI: 10.1016/j.canlet.2011.05.022
189. S. Yokota, N. Fujii: Immunomodulatory activity of extracellular heat shock proteins and their autoantibodies. *Microbiol Immunol*, 54, 299-307 (2010)  
DOI: 10.1111/j.1348-0421.2010.00214.x
190. J. E. Greenlee, S. A. Clawson, K. E. Hill, B. Wood, S. L. Clardy, I. Tsunoda, T. D. Jaskowski, N. G. Carlson: Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. *J Neuroinflammation*, 11, 160 (2014)  
DOI: 10.1186/s12974-014-0160-0
191. J. E. Greenlee, S. A. Clawson, K. E. Hill, B. L. Wood, I. Tsunoda, N. G. Carlson: Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. *J Neuropathol Exp Neurol*, 69, 997-1007 (2010)  
DOI: 10.1097/NEN.0b013e3181f0c82b
192. J. E. Greenlee, S. A. Clawson, K. E. Hill, B. Wood, S. L. Clardy, I. Tsunoda, N. G. Carlson: Anti-Yo Antibody Uptake and Interaction with Its Intracellular Target Antigen Causes Purkinje Cell Death in Rat Cerebellar Slice Cultures: A Possible Mechanism for Paraneoplastic Cerebellar Degeneration in Humans with Gynecological or Breast Cancers. *PLoS One*, 10, e0123446 (2015)  
DOI: 10.1371/journal.pone.0123446
193. H. B. Yang, W. J. Zheng, X. Zhang, F. L. Tang: Induction of endothelial cell apoptosis by anti-alpha-enolase antibody. *Chin Med*

- Sci J*, 26, 152-157 (2011)  
DOI: 10.1016/S1001-9294(11)60040-0
194. A. Magrys, T. Anekonda, G. Ren, G. Adamus: The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. *J Clin Immunol*, 27, 181-192 (2007)  
DOI: 10.1007/s10875-006-9065-8
195. M. Principe, P. Ceruti, N. Y. Shih, M. S. Chattaragada, S. Rolla, L. Conti, M. Bestagno, L. Zentilin, S. H. Yang, P. Migliorini, P. Cappello, O. Burrone, F. Novelli: Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. *Oncotarget*, 6, 11098-11113 (2015)  
DOI: 10.18632/oncotarget.3572
196. S. Kivity, Y. Shoenfeld, M. T. Arango, D. J. Cahill, S. L. O'Kane, M. Zusev, I. Slutsky, M. Harel-Meir, J. Chapman, T. Matthias, M. Blank: Anti-ribosomal-phosphoprotein autoantibodies penetrate to neuronal cells via neuronal growth associated protein, affecting neuronal cells *in vitro*. *Rheumatology (Oxford)*, pii: kew027 (2016)
197. A. Chernyavsky, Y. Chen, P. H. Wang, S. A. Grando: Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. *Int Immunopharmacol*, 29, 76-80 (2015)  
DOI: 10.1016/j.intimp.2015.04.046
198. A. Roberts, S. Perera, B. Lang, A. Vincent, J. Newsom-Davis: Paraneoplastic myasthenic syndrome IgG inhibits 45Ca<sup>2+</sup> flux in a human small cell carcinoma line. *Nature*, 317, 737-739 (1985)  
DOI: 10.1038/317737a0
199. C. A. Viall, Q. Chen, B. Liu, A. Hickey, S. Snowise, J. E. Salmon, P. R. Stone, L. W. Chamley: Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. *J Autoimmun*, 47, 45-57 (2013)  
DOI: 10.1016/j.jaut.2013.08.005
200. M. Pan, X. Liu, J. Zheng: The pathogenic role of autoantibodies in pemphigus vulgaris. *Clin Exp Dermatol*, 36, 703-707 (2011)  
DOI: 10.1111/j.1365-2230.2011.04092.x
201. J. Ratelade, A. S. Verkman: Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. *Int J Biochem Cell Biol*, 44, 1519-1530 (2012)  
DOI: 10.1016/j.biocel.2012.06.013
202. R. Marignier, A. Ruiz, S. Cavagna, A. Nicole, C. Watrin, M. Touret, S. Parrot, G. Malleret, C. Peyron, C. Benetollo, N. Auvergnon, S. Vukusic, P. Giraudon: Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. *J Neuroinflammation*, 18, 111 (2016)  
DOI: 10.1186/s12974-016-0577-8
203. M. Laffon, C. Giordana, F. Almairac, M. Benchetrit, P. Thomas: Anti-Hu-associated paraneoplastic limbic encephalitis in Hodgkin lymphoma. *Leuk Lymphoma*, 53, 1433-1434 (2012)  
DOI: 10.3109/10428194.2011.645211
204. M. Scharf, R. Miske, F. Heidenreich, R. Giess, P. Landwehr, I. M. Blöcker, N. Begemann, Y. Denno, S. Tiede, C. Dähnrich, W. Schlumberger, M. Unger, B. Teegen, W. Stöcker, C. Probst, L. Komorowski: Neuronal Na<sup>+</sup>/K<sup>+</sup> ATPase is an autoantibody target in paraneoplastic neurologic syndrome. *Neurology*, 84, 1673-1679 (2015)  
DOI: 10.1212/WNL.0000000000001493
205. L. Bataller, D. F. Wade, F. Graus, H. D. Stacey, M. R. Rosenfeld, J. Dalmau: Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. *Neurology*, 62, 778-782 (2004)  
DOI: 10.1212/01.WNL.0000113749.77217.01
206. A. Kerasnoudis, M. Rockhoff, J. Federlein, R. Gold, C. Krogias: Isolated ZIC4 antibodies in paraneoplastic cerebellar syndrome with an underlying ovarian tumor. *Arch Neurol*, 68, 1073 (2011)  
DOI: 10.1001/archneurol.2011.176
207. S. Ogita, O. H. Llaguna, S. M. Feldman, R. Blum: Paraneoplastic cerebellar degeneration with anti-Yo antibody in a patient with HER2/neu overexpressing breast cancer: a case report with a current literature review. *Breast J*, 14, 382-384 (2008)  
DOI: 10.1111/j.1524-4741.2008.00604.x
208. W. Waheed, J. Boyd, F. Khan, S. L. Mount, N. M. Borden, R. Tandan: Double trouble: para-neoplastic anti-PCA-2 and CRMP-5-mediated small fibre neuropathy followed by chorea associated with small cell lung cancer and evolving radiological features.

- BMJ Case Rep*, 2016, pii: bcr2016215158 (2016)  
DOI: 10.1136/bcr-2016-215158
209. R. Iorio, V. Damato, M. Mirabella, M. G. Vita, E. Hulsboom, D. Plantone, A. Bizzarro, A. Del Grande, P. A. Sillevs Smitt: Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. *J Neuroimmunol*, 263, 155-158 (2013)  
DOI: 10.1016/j.jneuroim.2013.07.015
210. S. M. Murphy, U. Khan, C. Alifrangis, S. Hazell, D. Hroudá, J. Blake, J. Ball, C. Gabriel, P. Markarian, J. Rees, A. Karim, M. J. Seckl, M. P. Lunn, M. M. Reilly: Anti Ma2-associated myeloradiculopathy: expanding the phenotype of anti-Ma2 associated paraneoplastic syndromes. *J Neurol Neurosurg Psychiatry*, 83, 232-233 (2012)  
DOI: 10.1136/jnnp.2010.223271
211. N. L. Zalewski, V. A. Lennon, D. H. Lachance, C. J. Klein, S. J. Pittock, A. Mckeon: P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. *Muscle Nerve*, 54, 220-227 (2016)  
DOI: 10.1002/mus.25027
212. W. H. Xiong, R. M. Duvoisin, G. Adamus, B. G. Jeffrey, C. Gellman, C. W. Morgans: Serum TRPM1 autoantibodies from melanoma associated retinopathy patients enter retinal on-bipolar cells and attenuate the electroretinogram in mice. *PLoS One*, 8, e69506 (2013)  
DOI: 10.1371/journal.pone.0069506
213. M. Kondo, R. Sanuki, S. Ueno, Y. Nishizawa, N. Hashimoto, H. Ohguro, S. Yamamoto, S. Machida, H. Terasaki, G. Adamus, T. Furukawa: Identification of autoantibodies against TRPM1 in patients with paraneoplastic retinopathy associated with ON bipolar cell dysfunction. *PLoS One*, 6, e19911 (2011)  
DOI: 10.1371/journal.pone.0019911
214. S. Ayyappan, T. Day, L. Kiers: Distal acquired demyelinating symmetric (DADS) neuropathy associated with colorectal adenocarcinoma. *Muscle Nerve*, 51, 928-931 (2015)  
DOI: 10.1002/mus.24510
215. L. Sabater, M. Titulaer, A. Saiz, J. Verschuuren, A. O. Güre, F. Graus: SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. *Neurology*, 70, 924-928 (2008)  
DOI: 10.1212/01.wnl.0000281663.81079.24
216. M. Frasset, L. Bataller, E. Torres-Vega, M. Durán-Moreno, J. M. García-Verdugo, T. Sevilla, S. Rivas, F. Pérez-Mirallas, M. Simó-Castelló, B. Casanova: Longitudinally extensive transverse myelitis with AQP4 antibodies revealing ovarian teratoma. *J Neuroimmunol*, 263, 145-147 (2013)  
DOI: 10.1016/j.jneuroim.2013.07.003
217. C. V. Verschuur, A. J. Kooij, D. Troost: Anti-aquaporin 4 related paraneoplastic neuromyelitis optica in the presence of adenocarcinoma of the lung. *Clin Neuropathol*, 34, 232-236 (2015)  
DOI: 10.5414/NP300855
218. S. M. Wali, A. Cai, A. M. Rossor, C. Clough: Appearance of anti-NMDAR antibodies after plasma exchange and total removal of malignant ovarian teratoma in a patient with paraneoplastic limbic encephalopathy. *BMJ Case Rep*, 2011, pii: bcr0220113851 (2011)  
DOI: 10.1136/bcr.02.2011.3851
219. L. Bataller, R. Galiano, M. García-Escrig, B. Martínez, T. Sevilla, R. Blasco, J. J. Vílchez, J. Dalmau: Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. *Neurology*, 74, 265-267 (2010)  
DOI: 10.1212/WNL.0b013e3181cb3e52
220. T. Asakura, S. Yoshida, A. Maeshima, K. Fujimoto, R. Jo, K. Iwase, Y. Oyamada: Small Cell Lung Cancer Expressing Glutamate Decarboxylase with Latent Autoimmune Diabetes in Adults. *Intern Med*, 54, 3035-3037 (2015)  
DOI: 10.2169/internalmedicine.54.4478
221. G. Piccolo, E. Tavazzi, T. Cavallaro, A. Romani, R. Scelsi, G. Martino: Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. *J Neurol Sci*, 290, 148-149 (2010)  
DOI: 10.1016/j.jns.2009.12.006
222. A. A. Yong, H. L. Tey: Paraneoplastic pemphigus. *Australas J Dermatol*, 54, 241-250 (2013)  
DOI: 10.1111/j.1440-0960.2012.00921.x

223. V. Racanelli, M. Prete, C. Minoia, E. Favoino, F. Perosa: Rheumatic disorders as paraneoplastic syndrome. *Autoimmun Rev*, 7, 352-358 (2008)  
DOI: 10.1016/j.autrev.2008.02.001
224. E. Larson, D. Etwaru, C. Siva, K. Lawlor: Report of anti-CCP antibody positive paraneoplastic polyarthritis and review of the literature. *Rheumatol Int*, 31, 1635-1638 (2011)  
DOI: 10.1007/s00296-009-1294-8
225. S.E. Billet, S.A. Grando, M.R. Pittelkow: Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. *Autoimmunity*, 39, 617-630 (2006)  
DOI: 10.1080/08916930600972099
226. A. Czernik, M. Camilleri, M. R. Pittelkow, S. A. Grando: Paraneoplastic autoimmune multiorgan syndrome: 20 years after. *Int J Dermatol*, 50, 905-914 (2011)  
DOI: 10.1111/j.1365-4632.2011.04868.x
227. J. Puthenparambil, K. Lechner, G. Kornek: Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. *Wien Klin Wochenschr*, 122, 229-236 (2010)  
DOI: 10.1007/s00508-010-1319-z
228. M. Ehrenfeld, M. Abu-Shakra, D. Buskila, Y. Shoenfeld: The dual association between lymphoma and autoimmunity. *Blood Cells Mol Dis*, 27, 750-756 (2001)  
DOI: 10.1006/bcmd.2001.0442
229. K. Järås, K. Anderson: Autoantibodies in cancer: prognostic biomarkers and immune activation. *Expert Rev Proteomics*, 8, 577-589 (2011)  
DOI: 10.1586/epr.11.48
230. K. Yanagita, R. Nagashio, S. Ryuge, K. Katono, S. X. Jiang, B. Tsuchiya, H. Nakashima, E. Fukuda, N. Goshima, M. Saegusa, Y. Satoh, N. Masuda, Y. Sato: Serum anti-Gal-3 autoantibody is a predictive marker of the efficacy of platinum-based chemotherapy against pulmonary adenocarcinoma. *Asian Pac J Cancer Prev*, 16, 7959-7965 (2015)  
DOI: 10.7314/APJCP.2015.16.17.7959
231. F. Fernández-Madrid, N. Tang, H. Alansari, J. L. Granda, L. Tait, K. C. Amirikia, M. Moroianu, X. Wang, R. L. Karvonen: Autoantibodies to Annexin XI-A and other autoantigens in the diagnosis of breast cancer. *Cancer Res*, 64, 5089-5096 (2004)  
DOI: 10.1158/0008-5472.CAN-03-0932
232. O. Blixt, D. Bueti, B. Burford, D. Allen, S. Julien, M. Hollingsworth, A. Gammerman, I. Fentiman, J. Taylor-Papadimitriou, J. M. Burchell: Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. *Breast Cancer Res*, 13, R25 (2011)  
DOI: 10.1186/bcr2841
233. C. Atalay, L. Dogan, G. Atalay: Anti-CENP-B antibodies are associated with prolonged survival in breast cancer. *Future Oncol*, 6, 471-477 (2010)  
DOI: 10.2217/fon.10.6
234. A. Kulić, M. Sirotković-Skerlev, S. Jelisavac-Cosić, D. Herceg, Z. Kovac, D. Vrbanec: Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients. *Med Oncol*, 27, 887-893 (2010)  
DOI: 10.1007/s12032-009-9301-1
235. P. Lenner, F. Wiklund, S. O. Emdin, C. Arnerlöv, C. Eklund, G. Hallmans, H. Zentgraf, J. Dillner: Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. *Br J Cancer*, 79, 927-932 (1999)  
DOI: 10.1038/sj.bjc.6690148
236. Y. Sun, R. Zhang, M. Wang, Y. Zhang, J. Qi, J. Li: SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma. *Cancer Epidemiol Biomarkers Prev*, 21, 2043-2047 (2012)  
DOI: 10.1158/1055-9965.EPI-12-0498
237. C. Desmetz, C. Bascoul-Molleivi, P. Rochaix, P. J. Lamy, A. Kramar, P. Rouanet, T. Maudelonde, A. Mangé, J. Solassol: Identification of a new panel of serum autoantibodies associated with the presence of *in situ* carcinoma of the breast in younger women. *Clin Cancer Res*, 15, 4733-4741 (2009)  
DOI: 10.1158/1078-0432.CCR-08-3307
238. Q. Zhu, S. X. Han, C. Y. Zhou, M. J. Cai, L. P. Dai, J. Y. Zhang: Autoimmune response to PARP and BRCA1/BRCA2 in cancer.



- Oncotarget*, 6, 11575-11584 (2015)  
DOI: 10.18632/oncotarget.3428
239. H. Lu, J. Ladd, Z. Feng, M. Wu, V. Goodell, S. J. Pitteri, C. I. Li, R. Prentice, S. M. Hanash, M. L. Disis: Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. *Cancer Prev Res (Phila)*, 5, 1036-1043 (2012)  
DOI: 10.1158/1940-6207.CAPR-11-0558
240. R. L. Evans, J. V. Pottala, K. A. Eglund: Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens. *Cancer Prev Res (Phila)*, 7, 545-555 (2014)  
DOI: 10.1158/1940-6207.CAPR-13-0416
241. H. Ye, C. Sun, P. Ren, L. Dai, B. Peng, K. Wang, W. Qian, J. Zhang: Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. *Oncol Lett*, 5, 663-668 (2013)  
DOI: 10.3892/ol.2012.1062
242. W. Liu, I. G. De La Torre, M. C. Gutiérrez-Rivera, B. Wang, Y. Liu, L. Dai, W. Qian, J. Y. Zhang: Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer. *Tumour Biol*, 36, 1307-1312 (2015)  
DOI: 10.1007/s13277-014-2756-5
243. U. Mack, D. Ukena, M. Montenarh, G. W. Sybrecht: Serum anti-p53 antibodies in patients with lung cancer. *Oncol Rep*, 7, 669-674 (2000)  
DOI: 10.3892/or.7.3.669
244. G. Zalcmán, J. Trédaniel, B. Schlichtholz, T. Urban, B. Milleron, R. Lubin, V. Meignin, L. J. Couderc, A. Hirsch, T. Soussi: Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. *Int J Cancer*, 89, 81-86 (2000)  
DOI: 10.1002/(SICI)1097-0215(20000120)89:1<81::AID-IJC13>3.0.CO;2-I
245. M. Neri, P. Betta, P. Marroni, R. Filiberti, M. Cafferata, C. Mereu, G. Ivaldi, F. Montanaro, R. Puntoni, M. Paganuzzi: Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases. *Lung Cancer*, 39, 165-172 (2003)  
DOI: 10.1016/S0169-5002(02)00449-X
246. M. R. Rosenfeld, N. Malats, L. Schramm, F. Graus, F. Cardenal, N. Viñolas, R. Rosell, M. Torà, F. X. Real, J. B. Posner, J. Dalmau: Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. *J Natl Cancer Inst*, 89, 381-384 (1997)  
DOI: 10.1093/jnci/89.5.381
247. Y. Segawa, M. Kageyama, S. Suzuki, K. Jinno, N. Takigawa, N. Fujimoto, K. Hotta, K. Eguchi: Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study. *Br J Cancer*, 78, 667-672 (1998)  
DOI: 10.1038/bjc.1998.557
248. W. Wang, S. Guan, S. Sun, Y. Jin, K. H. Lee, Y. Chen, J. Wei: Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. *Tumour Biol*, 35, 4901-4905 (2014)  
DOI: 10.1007/s13277-014-1643-4
249. L. Ma, W. Yue, Y. Teng, L. Zhang, M. Gu, Y. Wang: Serum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinoma. *Dis Markers*, 35, 317-325 (2013)  
DOI: 10.1155/2013/935943
250. Y. Zhang, X. Ying, S. Han, J. Wang, X. Zhou, E. Bai, J. Zhang, Q. Zhu: Autoantibodies against insulin-like growth factor binding protein-2 as a serological biomarker in the diagnosis of lung cancer. *Int J Oncol*, 42, 93-100 (2013)  
DOI: 10.3892/ijo.2012.1699
251. C. Zhang, L. Ye, S. Guan, S. Jin, W. Wang, S. Sun, K. H. Lee, J. Wei, B. Liu: Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. *Tumour Biol*, 35, 2047-2051 (2014)  
DOI: 10.1007/s13277-013-1271-4
252. S. Qi, M. Huang, H. Teng, Y. Lu, M. Jiang, L. Wang, J. Shi, Q. Ma, G. Gu, Y. Xin, H. Ma: Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer. *Tumour Biol*, 36, 9979-9985 (2015)  
DOI: 10.1007/s13277-015-3794-3
253. Y. Yao, Y. Fan, J. Wu, H. Wan, J. Wang, S. Lam, W. L. Lam, L. Girard, A. F. Gazdar, Z. Wu, Q. Zhou: Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis.

- Biochem Biophys Res Commun*, 423, 613-619 (2012)  
DOI: 10.1016/j.bbrc.2012.06.050
254. Q. Shan, X. Lou, T. Xiao, J. Zhang, H. Sun, Y. Gao, S. Cheng, L. Wu, N. Xu, S. Liu: A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. *Cancer Lett*, 328, 160-167 (2013)  
DOI: 10.1016/j.canlet.2012.08.019
255. P. Boyle, C. J. Chapman, S. Holdenrieder, A. Murray, C. Robertson, W. C. Wood, P. Maddison, G. Healey, G. H. Fairley, A. C. Barnes, J. F. Robertson: Clinical validation of an autoantibody test for lung cancer. *Ann Oncol*, 22, 383-389 (2011)  
DOI: 10.1093/annonc/mdq361
256. L. Dai, J. C. Tsay, J. Li, T. A. Yie, J. S. Munger, H. Pass, W. N. Rom, Y. Zhang, E. M. Tan, J. Y. Zhang: Autoantibodies against tumor-associated antigens in the early detection of lung cancer. *Lung Cancer*, 99, 172-179 (2016)  
DOI: 10.1016/j.lungcan.2016.07.018
257. P. Leidinger, A. Keller, N. Ludwig, S. Rheinheimer, J. Hamacher, H. Huwer, I. Stehle, H. P. Lenhof, E. Meese: Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. *Int J Cancer*, 123, 1631-1636 (2008)  
DOI: 10.1002/ijc.23680
258. E. C. Farlow, K. Patel, S. Basu, B. S. Lee, A. W. Kim, J. S. Coon, L. P. Faber, P. Bonomi, M. J. Liptay, J. A. Borgia: Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. *Clin Cancer Res*, 16, 3452-3462 (2010)  
DOI: 10.1158/1078-0432.CCR-09-3192
259. J. Wang, S. Shivakumar, K. Barker, Y. Tang, G. Wallstrom, J. G. Park, J. C. Tsay, H. I. Pass, W. N. Rom, J. LaBaer, J. Qiu: Comparative study of autoantibody responses between lung adenocarcinoma and benign pulmonary nodules. *J Thorac Oncol*, 11, 334-345 (2016)  
DOI: 10.1016/j.jtho.2015.11.011
260. J. Jia, W. Wang, W. Meng, M. Ding, S. Ma, X. Wang: Development of a multiplex autoantibody test for detection of lung cancer. *PLoS One*, 9, e95444 (2014)  
DOI: 10.1371/journal.pone.0095444
261. C. L. Lai, C. M. Tsai, T. T. Tsai, B. Kuo, K. T. Chang, H. T. Fu, R. P. Perng, J. Y. Chen: Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. *Clin Cancer Res*, 4, 3025-3030 (1998)
262. J. Laudanski, T. Burzykowski, W. Niklinska, K. Chyczewski, M. Furman, J. Niklinski: Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. *Lung Cancer*, 22, 191-200 (1998)  
DOI: 10.1016/S0169-5002(98)00088-9
263. F. Blaes, M. Klotz, H. Huwer, U. Straub, G. Kalweit, K. Schimrigk, H. J. Schäfers: Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. *Ann Thorac Surg*, 69, 254-258 (2000)  
DOI: 10.1016/S0003-4975(99)01198-4
264. T. Mitsudomi, S. Suzuki, Y. Yatabe, M. Nishio, M. Kuwabara, K. Gotoh, S. Hatooka, M. Shinoda, M. Suyama, M. Ogawa, T. Takahashi, Y. Ariyoshi, T. Takahashi: Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. *J Natl Cancer Inst*, 90, 1563-1568 (1998)  
DOI: 10.1093/jnci/90.20.1563
265. M. Bergqvist, D. Brattström, A. Larsson, P. Hesselius, O. Brodin, G. Wagenius: The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival. *BMC Cancer*, 4, 66 (2004)  
DOI: 10.1186/1471-2407-4-66
266. S. Guan, B. Liu, C. Zhang, K. H. Lee, S. Sun, J. Wei: Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma. *Clin Transl Oncol*, 15, 825-829 (2013)  
DOI: 10.1007/s12094-013-1007-3
267. L. Ye, S. Guan, C. Zhang, K. H. Lee, S. Sun, J. Wei, B. Liu: Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma. *Tumour Biol*, 34, 1873-1877 (2013)  
DOI: 10.1007/s13277-013-0729-8
268. Y. Jin, S. Guan, L. Liu, S. Sun, K. H. Lee, J. Wei: Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of

- esophageal cancer. *Asia Pac J Clin Oncol*, 11, e37-41 (2015)  
DOI: 10.1111/ajco.12198
269. H. F. Zhang, J. J. Qin, P. F. Ren, J. X. Shi, J. F. Xia, H. Ye, P. Wang, C. H. Song, K. J. Wang, J. Y. Zhang: A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer. *Cancer Immunol Immunother*, 65, 1233-1242 (2016)  
DOI: 10.1007/s00262-016-1886-6
270. M. Mattioni, S. Soddu, A. Porrello, R. D'Alessandro, A. Spila, F. Guadagni: Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. *Int J Biol Markers*, 22, 302-306 (2007)
271. P. Würl, F. Weigmann, A. Meye, M. Fittkau, U. Rose, D. Berger, F. W. Rath, H. Dralle, H. Taubert: Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. *Scand J Gastroenterol*, 32, 1147-1151 (1997)  
DOI: 10.3109/00365529709002995
272. L. L. Qiu, P. Y. Hua, L. L. Ye, Y. C. Wang, T. Qiu, H. Z. Bao, L. Wang L: The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. *Cancer Detect Prev*, 31, 45-49 (2007)  
DOI: 10.1016/j.cdp.2006.12.005
273. C. W. Wu, Y. Y. Lin, G. D. Chen, C. W. Chi, D. P. Carbone, J. Y. Chen: Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. *Br J Cancer*, 80, 483-488 (1999)  
DOI: 10.1038/sj.bjc.6690382
274. S. Tsunemi, T. Nakanishi, Y. Fujita, G. Bouras, Y. Miyamoto, A. Miyamoto, E. Nomura, T. Takubo, N. Tanigawa: Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. *Oncol Rep*, 23, 949-956 (2010)  
DOI: 10.3892/or\_00000719
275. S. Werner, H. Chen, J. Butt, A. Michel, P. Knebel, B. Holleczeck, I. Zörnig, S. B. Eichmüller, D. Jäger, M. Pawlita, T. Waterboer, H. Brenner: Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. *Sci Rep*, 6, 25467 (2016)  
DOI: 10.1038/srep25467
276. S. L. Zhou, J. W. Ku, Z. M. Fan, W. B. Yue, F. Du, Y. F. Zhou, Y. L. Liu, Y. Li, S. Tang, Y. L. Hu, X. P. Hu, Z. C. Hou, J. Liu, Y. Liu, X. S. Feng, L. D. Wang: Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma. *Dis Esophagus*, 28, 371-379 (2015)  
DOI: 10.1111/dote.12206
277. P. Zayakin, G. Ancāns, K. Siliņa, I. Meistere, Z. Kalniņa, D. Andrejeva, E. Endzeliņš, L. Ivanova, A. Pismennaja, A. Ruskule, S. Doniņa, T. Wex, P. Malfertheiner, M. Leja, A. Linē: Tumor-associated autoantibody signature for the early detection of gastric cancer. *Int J Cancer*, 132, 137-147 (2013)  
DOI: 10.1002/ijc.27667
278. G. Shiota, M. Ishida, N. Noguchi, K. Oyama, Y. Takano, M. Okubo, S. Katayama, Y. Tomie, K. Harada, K. Hori, K. Ashida, Y. Kishimoto, A. Hosoda, T. Suou, T. Kanbe, K. Tanaka, K. Nosaka, O. Tanida, H. Kojo, K. Miura, H. Ito, N. Kaibara, H. Kawasaki: Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. *Dig Dis Sci*, 45, 122-128 (2000)  
DOI: 10.1023/A:1005473729976
279. I. Babel, R. Barderas, R. Díaz-Uriarte, J. L. Martínez-Torrecedrada, M. Sánchez-Carbayo, J. I. Casal: Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. *Mol Cell Proteomics*, 8, 2382-2395 (2009)  
DOI: 10.1074/mcp.M800596-MCP200
280. M. M. Atta, S. A. el-Masry, M. Abdel-Hameed, H. A. Baiomy, N. E. Ramadan: Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. *Clin Biochem*, 41, 1131-1139 (2008)  
DOI: 10.1016/j.clinbiochem.2008.06.006
281. N. A. Gadelhak, S. A. Gadelhak, D. A. El-Morsi, M. M. Abdelaziz, A. T. Abbas, H. M. El-Emshaty: Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. *Hepatogastroenterology*, 56, 1417-1424 (2009)
282. Y. Chen, Y. Zhou, S. Qiu, K. Wang, S. Liu, X. X. Peng, J. Li, E. M. Tan, J. Y. Zhang: Autoantibodies to tumor-associated antigens

- combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. *Cancer Lett*, 289, 32-39 (2010)  
DOI: 10.1016/j.canlet.2009.07.016
283. L. Li, S. H. Chen, C. H. Yu, Y. M. Li, S. Q. Wang: Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. *J Proteome Res*, 7, 611-620 (2008)  
DOI: 10.1021/pr070525r
284. C. H. Middleton, W. Irving, J. F. Robertson, A. Murray, C. B. Parsy-Kowalska, I. K. Macdonald, J. McElveen, J. Allen, G. F. Healey, B. J. Thomson, S. J. Ryder, S. Holdenrieder, C. J. Chapman: Serum autoantibody measurement for the detection of hepatocellular carcinoma. *PLoS One*, 9, e103867 (2014)  
DOI: 10.1371/journal.pone.0103867
285. N. Charuruks, P. Tangkijvanich, N. Voravud, R. Chatsantikul, A. Theamboonlers, Y. Poovorawan: Clinical significance of p53 antigen and anti-p53 antibodies in the sera of hepatocellular carcinoma patients. *J Gastroenterol*, 36, 830-836 (2001)  
DOI: 10.1007/s005350170005
286. R. Saffroy, J. C. Lelong, D. Azoulay, M. Salvucci, M. Reynes, H. Bismuth, B. Debuire, A. Lemoine: Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. *Br J Cancer*, 79, 604-610 (1999)  
DOI: 10.1038/sj.bjc.6690095
287. J. Jiang, C. Wu, Y. Shen, B. Xu, X. Zheng, X. Li, N. Xu: Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma. *Anticancer Res*, 31, 687-691 (2011)  
DOI: 10.1002/jcla.20321
288. R. Bei, A. Budillon, M. G. Reale, G. Capuano, D. Pomponi, G. Budillon, L. Frati, R. Muraro: Cryptic epitopes on alpha-fetoprotein induce spontaneous immune responses in hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis patients. *Cancer Res*, 59, 5471-5474 (1999)
289. Q. Xia, X. T. Kong, G. A. Zhang, X. J. Hou, H. Qiang, R. Q. Zhong: Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. *Biochem Biophys Res Commun*, 330, 526-532 (2005)  
DOI: 10.1016/j.bbrc.2005.02.181
290. K. Angelopoulou, B. Rosen, M. Stratis, H. Yu, M. Solomou, E. P. Diamandis: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. *Cancer*, 78, 2146-2152 (1996)  
DOI: 10.1002/(SICI)1097-0142(19961115)78:10<2146::AID-CNCR15>3.0.CO;2-Z
291. B. Abendstein, C. Marth, E. Müller-Holzner, M. Widschwendter, G. Daxenbichler, A. G. Zeimet: Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. *Cancer*, 88, 1432-1437 (2000)  
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1432::AID-CNCR22>3.0.CO;2-8
292. K. S. Anderson, J. Wong, A. Vitonis, C. P. Crum, P. M. Sluss, J. Labaer, D. Cramer: p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. *Cancer Epidemiol Biomarkers Prev*, 19, 859-868 (2010)  
DOI: 10.1158/1055-9965.EPI-09-0880
293. E. V. Høgdall, C. K. Høgdall, J. Blaakaer, N. H. Heegaard, E. Glud, L. Christensen, J. E. Bock, B. Nørgaard-Pedersen, A. Wiik, S. K. Kjaer: P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. *APMIS*, 110, 545-553 (2002)  
DOI: 10.1034/j.1600-0463.2002.11007805.x
294. F. D. Vogl, M. Frey, R. Kreienberg, I. B. Runnebaum: Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. *Br J Cancer*, 83, 1338-1343 (2000)  
DOI: 10.1054/bjoc.2000.1446
295. A. A. Karabudak, J. Hafner, V. Shetty, S. Chen, A. A. Secord, M. A. Morse, R. Philip: Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels. *J Cancer Res Clin Oncol*, 139, 1757-1770 (2013)  
DOI: 10.1007/s00432-013-1501-6
296. K. S. Anderson, D. W. Cramer, S. Sibani, G. Wallstrom, J. Wong, J. Park, J. Qiu, A. Vitonis, J. LaBaer: Autoantibody signature for the serologic detection of ovarian cancer.

- J Proteome Res*, 14, 578-586 (2015)  
DOI: 10.1021/pr500908n
297. M. Garziera, M. Montico, E. Bidoli, S. Scalone, R. Sorio, G. Giorda, E. Lucia, G. Toffoli: Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis. *PLoS One*, 10, e0140351 (2015)  
DOI: 10.1371/journal.pone.0140351
298. P. Massoner, A. Lueking, H. Goehler, A. Höpfner, A. Kowald, K. G. Kugler, P. Amersdorfer, W. Horninger, G. Bartsch, P. Schulz-Knappe, H. Klocker: Serum-autoantibodies for discovery of prostate cancer specific biomarkers. *Prostate*, 72, 427-436 (2012)  
DOI: 10.1002/pros.21444
299. P. Leidinger, A. Keller, L. Milchram, C. Harz, M. Hart, A. Werth, H. P. Lenhof, A. Weinhäusel, B. Keck, B. Wullich, N. Ludwig, E. Meese: Combination of autoantibody signature with PSA level enables a highly accurate blood-based differentiation of prostate cancer patients from patients with benign prostatic hyperplasia. *PLoS One*, 10, e0128235 (2015)  
DOI: 10.1371/journal.pone.0128235
300. B. Schlick, P. Massoner, A. Lueking, P. Charoentong, M. Blattner, G. Schaefer, K. Marquart, C. Theek, P. Amersdorfer, D. Zielinski, M. Kirchner, Z. Trajanoski, M. A. Rubin, S. Müllner, P. Schulz-Knappe, H. Klocker: Serum autoantibodies in chronic prostate inflammation in prostate cancer patients. *PLoS One*, 11, e0147739 (2016)  
DOI: 10.1371/journal.pone.0147739
301. K. Ait-Tahar, C. Damm-Welk, B. Burkhardt, M. Zimmermann, W. Klapper, A. Reiter, K. Pulford, W. Woessmann: Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. *Blood*, 115, 3314-3319 (2010)  
DOI: 10.1182/blood-2009-11-251892
302. R. B. Darnell, L. M. DeAngelis: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. *Lancet*, 341, 21-22 (1993)  
DOI: 10.1016/0140-6736(93)92485-C
303. M. L. Albert, R. B. Darnell: Paraneoplastic neurological degenerations: keys to tumour immunity. *Nat Rev Cancer*, 4, 36-44 (2004)  
DOI: 10.1038/nrc1255
304. P. Maddison, B. Lang, K. Mills, J. Newsom-Davis: Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. *J Neurol Neurosurg Psychiatry*, 70, 212-217 (2001)  
DOI: 10.1136/jnnp.70.2.212
305. J. Dalmau, F. Graus, M. K. Rosenblum, J. B. Posner: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. *Medicine (Baltimore)*, 71, 59-72 (1992)  
DOI: 10.1097/00005792-199203000-00001
306. K. Peterson, M. K. Rosenblum, H. Kotanides, J. B. Posner: Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. *Neurology*, 42, 1931-1937 (1992)  
DOI: 10.1212/WNL.42.10.1931
307. F. Graus, F. Keime-Guibert, R. Refe, B. Benyahia, T. Ribalta, C. Ascaso, G. Escaramis, J. Y. Delattre: Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. *Brain*, 124, 1138-1148 (2001)  
DOI: 10.1093/brain/124.6.1138
308. J. Honnorat, S. Cartalat-Carel, D. Ricard, J. P. Camdessanche, A. F. Carpentier, V. Rogemond, F. Chapuis, M. Aguera, E. Decullier, A. M. Duchemin, F. Graus, J. C. Antoine: Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. *J Neurol Neurosurg Psychiatry*, 80, 412-416 (2009)  
DOI: 10.1136/jnnp.2007.138016
309. D. J. Hetzel, C. R. Stanhope, B. P. O'Neill, V. A. Lennon: Gynecologic cancer in patients with subacute cerebellar degeneration predicted by anti-Purkinje cell antibodies and limited in metastatic volume. *Mayo Clin Proc*, 65, 1558-1563 (1990)  
DOI: 10.1016/S0025-6196(12)62189-2
310. P. Gozzard, C. Chapman, A. Vincent, B. Lang, P. Maddison: Novel humoral prognostic markers in small-cell lung carcinoma: a prospective study. *PLoS One*, 10, e0143558 (2015)  
DOI: 10.1371/journal.pone.0143558
311. I. Rojas, F. Graus, F. Keime-Guibert, R. Refe, J. Y. Delattre, J. M. Ramón, J. Dalmau,

- J. B. Posner: Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. *Neurology*, 55, 713-715 (2000)  
DOI: 10.1212/WNL.55.5.713
312. W. Zaheer, M. L. Friedland, E. B. Cooper, A. DoRosario, R. M. Burd, J. Gagliardi, G. Torstenson: Spontaneous regression of small cell carcinoma of lung associated with severe neuropathy. *Cancer Invest*, 11, 306-309 (1993)  
DOI: 10.3109/07357909309024856
313. E. Mawhinney, O. M. Gray, F. McVerry, G. V. McDonnell: Paraneoplastic sensorimotor neuropathy associated with regression of small cell lung carcinoma. *BMJ Case Rep*, 2010, pii: bcr0120091486 (2010)  
DOI: 10.1136/bcr.01.2009.1486
314. S. Gill, N. Murray, J. Dalmau, B. Thiessen: Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. *Can J Neurol Sci*, 30, 269-271 (2003)  
DOI: 10.1017/S0317167100002729
315. S. Hirano, Y. Nakajima, E. Morino, Y. Fujikura, M. Mochizuki, Y. Takeda, H. Sugiyama, N. Kobayashi, K. Tanaka, K. Kudo: A case of spontaneous regression of small cell lung cancer with progression of paraneoplastic sensory neuropathy. *Lung Cancer*, 58, 291-295 (2007)  
DOI: 10.1016/j.lungcan.2007.05.005
316. A. Villers, M. C. Lami, P. Filoche, S. Milinkevitch, J. M. Goujon, G. Guillet: Regression of primary melanoma with metastases associated with amyopathic dermatomyositis. *Ann Dermatol Venerol*, 133, 573-576 (2006)  
DOI: 10.1016/S0151-9638(06)70966-8
317. G. O'Malley, M. Heijltjes, A. M. Houston, S. Rani, T. Ritter, L. J. Egan, A. E. Ryan: Mesenchymal stromal cells (MSCs) and colorectal cancer - a troublesome twosome for the anti-tumour immuneresponse? *Oncotarget* (2016)  
DOI: 10.18632/oncotarget.11354
318. S. G. Kalathil, Y. Thanavala: High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. *Cancer Immunol Immunother*, 65, 813-819 (2016)  
DOI: 10.1007/s00262-016-1810-0
319. D. M. Pardoll: The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer*, 12, 252-264 (2012)  
DOI: 10.1038/nrc3239
320. M. van der Vlist, J. Kuball, T. R. Radstake, L. Meyaard: Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? *Nat Rev Rheumatol*, 12, 593-604 (2016)  
DOI: 10.1038/nrrheum.2016.131
321. P. Sharma, J. P. Allison: The future of immune checkpoint therapy. *Science*, 348, 56-61 (2015)  
DOI: 10.1126/science.aaa8172
322. A. Swaika, W. A. Hammond, R. W. Joseph: Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. *Mol Immunol*, 67, 4-17 (2015)  
DOI: 10.1016/j.molimm.2015.02.009
323. J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, N. H. Segal, C. E. Ariyan, R. A. Gordon, K. Reed, M. M. Burke, A. Caldwell, S. A. Kronenberg, B. U. Agunwamba, X. Zhang, I. Lowy, H. D. Inzunza, W. Feely, C. E. Horak, Q. Hong, A. J. Korman, J. M. Wigginton, A. Gupta, M. Sznol: Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med*, 369, 122-133 (2013)  
DOI: 10.1056/NEJMoa1302369
324. B. Boyerinas, C. Jochems, M. Fantini, C. R. Heery, J. L. Gulley, K. Y. Tsang, J. Schlom: Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. *Cancer Immunol Res*, 3, 1148-1157 (2015)  
DOI: 10.1158/2326-6066.CIR-15-0059
325. C. Jochems, M. Fantini, R. I. Fernando, A. R. Kwilas, R. N. Donahue, L. M. Lepone, I. Grenga, Y. S. Kim, M. W. Brechbiel, J. L. Gulley, R. A. Madan, C. R. Heery, J. W. Hodge, R. Newton, J. Schlom, K. Y. Tsang: The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. *Oncotarget*, 7, 37762-37772 (2016)
326. L. Min, F. S. Hodi: Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. *Cancer Immunol Res*, 2, 15-18 (2014)  
DOI: 10.1158/2326-6066.CIR-13-0146

327. M. Ryder, M. Callahan, M. A. Postow, J. Wolchok, J. A. Fagin: Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. *Endocr Relat Cancer*, 21, 371-381 (2014)  
DOI: 10.1530/ERC-13-0499
328. J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, A. Berdelou, A. Varga, R. Bahleda, A. Hollebecque, C. Massard, A. Fuerea, V. Ribrag, A. Gazzah, J. P. Armand, N. Amellal, E. Angevin, N. Noel, C. Boutros, C. Mateus, C. Robert, J. C. Soria, A. Marabelle, O. Lambotte: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer*, 54, 139-148 (2016)  
DOI: 10.1016/j.ejca.2015.11.016
329. L. Zhang, W. Qian, Q. Chen, L. Yin, B. Li, H. Wang: Imbalance in circulating T lymphocyte subsets contributes to Hu antibody associated paraneoplastic neurological syndromes. *Cell Immunol*, 290, 245-250 (2014)  
DOI: 10.1016/j.cellimm.2014.06.009
330. T. Tani, K. Tanaka, J. Idezuka, M. Nishizawa: Regulatory T cells in paraneoplastic neurological syndromes. *J Neuroimmunol*, 196, 166-169 (2008)  
DOI: 10.1016/j.jneuroim.2008.03.002
331. Y. Wang, J. Sun, R. Zheng, Q. Shao, W. Gao, B. Song, X. Chen, X. Qu: Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis. *Neoplasma*, 63, 789-798 (2016)  
DOI: 10.4149/neo\_2016\_517
332. W. Józwicki, A. A. Brożyna, J. Siekiera, A. T. Slominski: Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. *Oncotarget*, 7, 11450-11462 (2016)  
DOI: 10.1016/j.semcan.2015.03.004
333. A. M. Heeren, E. de Boer, M. C. Bleeker, R. J. Musters, M. R. Buist, G. G. Kenter, T. D. de Gruijl, E. S. Jordanova: Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. *Oncotarget*, 6, 32484-32493 (2015)  
DOI: 10.1038/cmi.2015.12
334. D. S. Vinay, E. P. Ryan, G. Pawelec, W. H. Talib, J. Stagg, E. Elkord, T. Lichter, W. K. Decker, R. L. Whelan, H. M. Kumara, E. Signori, K. Honoki, A. G. Georgakilas, A. Amin, W. G. Helferich, C. S. Boosani, G. Guha, M. R. Ciriolo, S. Chen, S. I. Mohammed, A. S. Azmi, W. N. Keith, A. Bilsland, D. Bhakta, D. Halicka, H. Fujii, K. Aquilano, S. S. Ashraf, S. Newsheen, X. Yang, B. K. Choi, B. S. Kwon: Immune evasion in cancer: mechanistic basis and therapeutic strategies. *Semin Cancer Biol*, 35, S185-S198 (2015)  
DOI: 10.1016/j.semcan.2015.03.004
335. J. Guo, X. Zhou: Regulatory T cells turn pathogenic. *Cell Mol Immunol*, 12, 525-532 (2015)  
DOI: 10.1038/cmi.2015.12
336. F. Barzaghi, L. Passerini, R. Bacchetta: Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. *Front Immunol*, 3, 211 (2012)  
DOI: 10.3389/fimmu.2012.00211
337. M. Dwivedi, E. H. Kemp, N. C. Laddha, M. S. Mansuri, A. P. Weetman, R. Begum: Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. *Autoimmun Rev*, 14, 49-56 (2015)  
DOI: 10.1016/j.autrev.2014.10.002
338. F. A. Cooles, J. D. Isaacs, A. E. Anderson: Treg cells in rheumatoid arthritis: an update. *Curr Rheumatol Rep*, 15, 352 (2013)  
DOI: 10.1007/s11926-013-0352-0
339. M. Battaglia, M. G. Roncarolo: Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. *Semin Immunol*, 23, 182-194 (2011)  
DOI: 10.1016/j.smim.2011.07.007
340. Y. C. Kong, G. P. Morris, N. K. Brown, Y. Yan, J. C. Flynn, C. S. David: Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function. *J Autoimmun*, 33, 239-246 (2009)  
DOI: 10.1016/j.jaut.2009.09.004

**Abbreviations:** Treg: regulatory T cell; MHC: Major histocompatibility complex; Jo-1: Istdil-tRNA sintetasi; Sm: Smith antigens; snRNP: Small nuclear ribonucleoproteins; SLE: Systemic lupus erithematosus; RA: Rheumatoid arthritis; eIF-4G: Eukaryotic translation initiation factor-4G; CCP:



Cyclic citrullinated peptide; RF: Rheumatoid factor; ASMA: Anti-smooth muscle antibodies; TPO: Thyroid peroxidase; TG: Thyroglobulin; TSH-R: Thyroid stimulating hormone receptor; ECM: extracellular matrix; HSP: Heat shock protein; GRP78: Glucose-regulated protein 78; HCC: Hepatocellular carcinoma; GAD: Glutamic acid decarboxylase; CA II: Carbonic anhydrase II; GADPH: Glyceraldehyde 3-phosphate dehydrogenase; SOD: Superoxide dismutase; ER: Estrogen receptor; AchR: Acetylcholine receptor; VGCC: Voltage-gated calcium channels; CD20: B-lymphocyte antigen CD20; Dsg: Desmoglein; IMP: Insulin-like growth factor II mRNA-binding protein; IFN: Interferon;  $\alpha_2$ -HSG:  $\alpha_2$ -Heremans Schmid-glycoprotein; TCR: T-cell receptor; ANA: Anti-nuclear antibodies; CENP: centromere nuclear protein; IL: Interleukin; EGFR: Epidermal growth factor receptor; ACPA: Anti-citrullinated proteins antibody; TNF: Tumor necrosis factor; NF- $\kappa$ B: Nuclear factor- $\kappa$ B; TLR: Toll-like receptor; ANCA: Anti-neutrophil cytoplasmic antibody; ROS: Reactive oxygen species; ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity; Erk: Extracellular signal-regulated kinases; Akt: Protein kinase B; PV: Pemphigus vulgaris; SCLC: Small cell lung cancer; TF: Tissue factor; VEGF: Vascular endothelial growth factor; FasR: Fas receptor; ZIC4: Zinc finger protein of cerebellum; CV2/CRMP-5: Collapsin response-mediator protein-5; mGluR1: Metabotropic glutamate receptor type 1; PCA: Purkinje cell cytoplasmic antibody; TRMP1: transient receptor potential cation channel, subfamily M, member 1; DADS: Distal acquired demyelinating symmetric; MAG: Myelin-associated glycoprotein; NMDAR: N-methyl-D-aspartate receptor; AMPAR: Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; PGA2: Polyglandular autoimmune syndrome type 2; MUC: mucin; FKBP: FK506 binding protein; PPIA: Peptidylprolyl isomerase A; PRDX: peroxiredoxin; PARP1: Poly(ADP-ribose) polymerase 1; BRCA2: Breast related cancer antigen 2; HER2: Receptor tyrosine-protein kinase erbB-2; CEA: carcinoembryonic antigen; DFS: disease-free survival; OS: overall survival; CCNY: Cyclin Y; IGFBP2: Insulin-like growth factor-binding protein 2; SMOX: spermine oxidase; NOLC1: Nucleolar and coiled-body phosphoprotein 1; MALAT1: Metastasis-associated lung adenocarcinoma transcript 1; HMMR: Hyaluronan mediated motility receptor; XAGE-1: X antigen family member-1; ADAM29: ADAM metallopeptidase domain 29; MAGEC1: MAGE family member C1; CAGE: Cancer-associated gene; BIRC: Baculoviral inhibitors of apoptosis repeat containing; CD25: Alpha chain of the IL-2 receptor; FOXP3: Forkhead box

P3; CTAG: cancer/testis antigen 1; SDCCAG8: Serologically defined colon cancer antigen 8; MAPKAPK3: MAP kinase-activated protein kinase 3; ACVR2B: Activin receptor type-2B; DDX: DEAD-box protein; MUT: Methylmalonyl-CoA mutase; CSRP2: Cysteine and glycine-rich protein 2; SPOP: Speckle-type POZ protein; ZNF671: Zinc finger protein 671; ALK: Anaplastic lymphoma kinase; MSC: Mesenchymal stromal cell; TGF: Transforming growth factor; MDSC: Myeloid-derived suppressor cell; TAM: Tumor-associated macrophage; CTLA4: Cytotoxic T-lymphocyte associated protein 4; PD1: Programmed cell death protein 1; TIM3: T-cell membrane protein 3; A2aR: Adenosine A2a receptor; LAG3: Lymphocyte activation gene 3; IRAE: Immune-related adverse events; ACTH: Adrenocorticotrophic hormone; FSH: follicle-stimulating hormone; LH: luteinising hormone; RANKL: Receptor activator of nuclear factor kappa-B ligand

**Key Words:** Tumor antigens, Autoantibodies, Paraneoplastic Syndromes, Autoimmunity, Tregs, Review

**Send correspondence to:** Roberto Bei, Dept. of Clinical Sciences and Translational Medicine, Faculty of Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Rome, Italy, Tel: 39 06-72596522, Fax: 39 06-72596506, E-mail: bei@med.uniroma2.it.